Doxorubicin conjugated to D-alpha-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS): In vitro cytotoxicity, in vivo Pharmacokinetics and Biodistribution by CAO NA
 DOXORUBICIN CONJUGATED TO D-α-TOCOPHERYL 
POLYETHYLENE GLYCOL 1000 SUCCINATE (TPGS): 
IN VITRO CYTOTOXICITY, IN VIVO 









A THESIS SUBMITTED FOR THE DEGREE OF MASTER 
OF ENGINEERING 
DEPARTMENT OF CHEMICAL AND BIOMOLECULAR 
ENGINEERING 
NATIONAL UNIVERSITY OF SINGAPORE 
2007
                 
 ACKNOWLEDGEMENTS 
 
First of all, I would like to take this opportunity to express my deepest gratitude and 
appreciation to the following people: 
 
My supervisor, Associate Professor Feng Si-Shen, for his invaluable advice, guidance, 
unconditional support and encouragement during the period of my research in Chemical & 
Biomolecular Engineering. I have learnt how to carry out research work, how to overcome 
the difficulty in research.  
 
My senior, Zhang Zhiping, for his unconditional support and invaluable advice in the 
study. His sharing on research experience as well as his help in training is greatly 
appreciated. 
 
My Laboratory colleagues, Dr. Dong Yuancai, Miss Lee Siehuey, Miss Chen Shilin, Dr. 
Mei Lin, Mr. Pan Jie, Ms Sun Bingfeng and others, for their kind support. 
 
Lab officers, Ms. Tan Mei Yee Dinah, Mr. Beoy Kok Hong, Ms. Chai Keng, Mr. Chia Pai 
Ann, Ms. Sandy Koh, Dr. Yuan Zeliang and others I may neglect to mention here, for 
their kind assistance. 
 
The financial support provided by National University of Singapore in the form of GST 
stipend is greatly acknowledged. 
                                                                                                    i
 TABLE OF CONTENT 
 
ACKNOWLEDGEMENTS ................................................................................................. i 
TABLE OF CONTENT...................................................................................................... ii 
SUMMARY...................................................................................................................... vii 
NOMENCLATURE .......................................................................................................... ix 
LIST OF TABLES............................................................................................................. xi 
LIST OF FIGURES .......................................................................................................... xii 
LIST OF SCHEMES........................................................................................................ xiv 
1 INTRODUCTION ....................................................................................................... 1 
1.1 General Background ...................................................................................... 1 
1.2 Objective and Thesis Organization................................................................ 4 
2 LITERATURE SURVEY............................................................................................ 6 
2.1 Cancer and Cancer Chemotherapy................................................................. 6 
2.1.1 Cancer ..................................................................................................... 6 
2.1.2 Cancer Treatment.................................................................................... 7 
2.1.3 Cancer Chemotherapy............................................................................. 8 
2.1.4 Problems in Chemotherapy..................................................................... 9 
2.1.5 Chemotherapeutic Engineering............................................................. 10 
2.2 Polymeric Drug Carrier................................................................................ 11 
2.2.1 Polymers as Drug Carrier...................................................................... 11 
2.2.1.1 Biodegradable Polymers................................................................ 11 
2.2.1.2 Polyethylene Glycol ...................................................................... 15 
                                                                                                    ii
 2.2.2 Polymeric Drug Formulations............................................................... 16 
2.2.2.1 Paste............................................................................................... 16 
2.2.2.2 Micelles ......................................................................................... 17 
2.2.2.3 Liposomes ..................................................................................... 19 
2.2.2.4 Microspheres ................................................................................. 21 
2.2.2.5 Nanoparticles................................................................................. 22 
2.3 Prodrug......................................................................................................... 23 
2.3.1 Design and Synthesis of Polymeric Prodrugs....................................... 24 
2.3.1.1 N-hydroxysuccinimide (NHS) Ester Coupling Method................ 25 
2.3.1.2 Carbodiimide Coupling Method.................................................... 26 
2.3.1.3 Dextran-prodrug ............................................................................ 28 
2.3.1.4 N-(2-hydroxypropyl)methacrylamide (HPMA)-prodrug .............. 30 
2.3.1.5 Dendrimer Conjugates................................................................... 31 
2.3.2 PEGylated Drug Conjugation ............................................................... 34 
2.3.2.1 PEGylation of Small Organic Molecules ...................................... 34 
2.3.2.2 PEGylation of Polypeptide (Peptides and Proteins)...................... 36 
2.3.2.3 Targeting PEGylation.................................................................... 37 
2.4 Vitamin E TPGS .......................................................................................... 38 
2.4.1 Chemistry of Vitamin E TPGS ............................................................. 38 
2.4.2 Solubilizer for Water-insoluble Compounds ........................................ 40 
2.4.3 Absorption Enhancer ............................................................................ 41 
2.4.4 Bioavailability Enhancer....................................................................... 41 
2.4.5 Anticancer Enhancer ............................................................................. 44 
2.4.6 Drug Delivery Applications.................................................................. 45 
                                                                                                    iii
 2.5 Doxorubicin ................................................................................................. 46 
2.5.1 History................................................................................................... 46 
2.5.2 Mechanism of Action............................................................................ 47 
2.5.3 Side Effects and Limitations................................................................. 49 
2.5.4 Formulations ......................................................................................... 50 
3 SYNTHESIS AND CHARACTERIZATION OF THE TPGS-DOX CONJUGATE52 
3.1 Introduction.................................................................................................. 52 
3.2 Experiment Section...................................................................................... 52 
3.2.1 Materials ............................................................................................... 52 
3.2.2 Synthesis of TPGS-DOX ...................................................................... 53 
3.2.2.1 TPGS Succinoylation .................................................................... 53 
3.2.2.2 TPGS-DOX Conjugation .............................................................. 54 
3.2.3 Characterization of TPGS-DOX Conjugate.......................................... 55 
3.2.3.1 FT-IR ............................................................................................. 55 
3.2.3.2 1H NMR......................................................................................... 56 
3.2.3.3 GPC ............................................................................................... 56 
3.2.3.4 Drug Conjugate Efficiency............................................................ 56 
3.2.3.5 Stability of the Conjugate.............................................................. 57 
3.3 Results and Discussion ................................................................................ 57 
3.3.1 FT-IR Spectra........................................................................................ 57 
3.3.2 1H NMR Spectra ................................................................................... 58 
3.3.3 GPC Results .......................................................................................... 59 
3.3.4 Drug Loading Capacity......................................................................... 61 
3.3.5 In Vitro Stability ................................................................................... 62 
                                                                                                    iv
 3.4 Conclusions.................................................................................................. 62 
4 IN VITRO STUDIES ON DURG RELEASE KINETICS, CELLULAR UPTAKE 
AND CELL CYTOTOXICITY OF THE TPGS-DOX CONJUGATE............................ 63 
4.1 Introduction.................................................................................................. 63 
4.2 Materials and Methods................................................................................. 63 
4.2.1 Materials ............................................................................................... 63 
4.2.2 In Vitro Drug Release ........................................................................... 64 
4.2.3 Cell Culture........................................................................................... 64 
4.2.4 In Vitro Cell Uptake Efficiency ............................................................ 64 
4.2.5 Confocal Laser Scanning Microscopy .................................................. 65 
4.2.6 In Vitro Cytotoxicity ............................................................................. 65 
4.2.7 Statistics ................................................................................................ 66 
4.3 Results and Discussion ................................................................................ 66 
4.3.1 In Vitro Drug Release ........................................................................... 66 
4.3.2 In Vitro Cellular Uptake........................................................................ 68 
4.3.3 Confocal Laser Scanning Microscopy .................................................. 72 
4.3.4 In Vitro Cytotoxicity ............................................................................. 74 
4.4 Conclusions.................................................................................................. 79 
5 IN VIVO INVESTIGATION ON PHARMACOKINETICS AND 
BIODISTRIBUTION OF THE TPGS-DOX CONJUGATE ........................................... 81 
5.1 Introduction.................................................................................................. 81 
5.2 Materials and Methods................................................................................. 81 
5.2.1 Animal................................................................................................... 81 
5.2.2 In Vivo Pharmacokinetics ..................................................................... 82 
                                                                                                    v
 5.2.2.1 Drug Administration...................................................................... 82 
5.2.2.2 Blood Collection and Sample Analysis......................................... 82 
5.2.2.3 Pharmacokinetic Parameters ......................................................... 83 
5.2.3 In Vivo Biodistribution.......................................................................... 84 
5.2.3.1 Drug Administration...................................................................... 84 
5.2.3.2 Tissues Collection and Samples Analysis ..................................... 84 
5.2.3.3 Statistics......................................................................................... 85 
5.3 Results and Discussion ................................................................................ 85 
5.3.1 Pharmacokinetics .................................................................................. 85 
5.3.2 Biodistribution ...................................................................................... 88 
5.4 Conclusions.................................................................................................. 91 
6 CONCLUSIONS AND RECOMMENDATIONS .................................................... 93 
6.1 Conclusions.................................................................................................. 93 
6.2 Recommendations........................................................................................ 95 








                                                                                                    vi
 SUMMARY 
 
Polymer-drug conjugation is one of the major strategies for drug modifications, which 
manipulate therapeutic agents at molecular level to increase their solubility, permeability 
and stability, and thus biological activity. Polymer-drug conjugation can significantly 
change biodistribution of the therapeutic agent, thus improving its pharmacokinetics (PK) 
and pharmacodynamics (PD), increasing their therapeutic effects and reducing their side 
effects, as well as provide a means to circumvent the multi-drug resistance (MDR). D-α-
tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or simply, TPGS), a 
water-soluble derivative of natural Vitamin E, is a PEGylated vitamin E, which is formed 
by esterification of vitamin E succinate with PEG 1000. Its amphiphilic structure, 
comprising lipophilic alkyl tail and hydrophilic polar head, is bulky and has large surface 
areas, which enables it to be an effective emulsifier and solubilizer. TPGS has been 
intensively used in our research either as an effective macromolecular emulsifier or as a 
component for a novel biodegradable copolymer PLA-TPGS for nanoparticle formulation 
of therapeutic agents, which resulted in high drug encapsulation efficiency, high cellular 
uptake and high in vitro cytotoxicity and in vivo therapeutic effects. Some reports 
demonstrated that TPGS can increase the oral bioavailability and enhance cytotoxicity of 
drugs. TPGS-drug conjugation should thus be an ideal solution for the drugs that have 
problems in their adsorption, distribution, metabolism and excretion (ADME). 
 
The aim of this study was to develop a novel TPGS-DOX conjugate to enhance the 
therapeutic potential and reduce the systemic side effects of the drug, doxorubicin. In this 
                                                                                                    vii
 research a novel prodrug, TPGS-doxorubicin conjugate, was successfully developed. The 
hydroxyl terminal group of TPGS was activated by succinic anhydride (SA) and interacted 
with the primary amine group of doxorubicin. The polymer-drug conjugation was 
confirmed by 1H NMR, FT-IR and GPC to characterize the molecular structure and 
molecular weight. The efficiency was determined to be 8% and stability of the conjugate 
was also favorable for required storage period. The drug release from the conjugate was 
pH dependent without significant initial burst. The cellular uptake, intracellular 
distribution, and cytotoxicity of the polymer-drug conjugation were accessed with MCF-7 
breast cancer cells and C6 glioma cells as in vitro model. The conjugate showed higher 
cellular uptake and broader distribution within the cells. Judged by IC50, the conjugate was 
found 31.8, 69.6, 84.1% more effective with MCF-7 cells and 43.9, 87.7, 42.2% more 
effective with C6 cells than the pristine drug in vitro after 24, 48, 72 h culture, 
respectively. In vivo pharmacokinetics confirmed the advantages of the prodrug. The area-
under-the-curve (AUC) was found to be 6,810 h·ng/mL for the prodrug but 289 h·ng/mL 
for the doxorubicin, which implied 23.6 times more effective, and the half-life of the drug 
is 9.65±0.94 h for the TPGS-DOX conjugation but 2.53±0.26 h for the original DOX, 
which implied 3.81 times longer (p<0.01), at the 5 mg/kg DOX dose i.v. injection. Effects 
of the conjugation on biodistribution showed the impaired systemic toxicity, especially for 
heart, stomach and intestine. 
 
The TPGS-DOX prodrug showed great potential to become a novel dosage form of 
doxorubicin and may also be applied to other anticancer drugs. 
 




AUC The area under the curve 
BBB Blood brain barrier 
BD Biodistribution 
CL Clearance 
CLSM Confocal laser scanning microscopy 
CMC Critical micelle concentration 




DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DOX Doxorubicin 
FBS Fetal bovine serum 
FT-IR Fourier transform infrared spectroscopy 
GI Gastrointestinal 
GPC Gel permeation chromatography 
HPLC High performance liquid chromatography 
HPMA N-(2-hydroxypropyl)methacrylamine 
IC50 The drug concentration at which 50% of the cell growth is inhibited
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 MDR Multi-drug resistance 
MRT Mean residence time 
MTD Maximum tolerated dose 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NHS N-hydroxysuccinimide 
NMR Nuclear magnetic resonance spectroscopy 
PBS Phosphate-buffered saline 
PEG Poly(ethylene glycol) 
PGA Poly(L-glutamic acid) 
P-gp P-glycoprotein 
PK Pharmacokinetics 
SA Succinic anhydride 
t1/2 Half-life time 
TEA Triethylanmine 
teffect Therapeutic effective period 
THF Tetrahydrofuran 
TPGS 
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 1 INTRODUCTION 
 
1.1  General Background 
Prodrug is a pharmacological substance in an inactive (or significantly less active) form 
that is formulated through transient modification of a given drug. In other words, a 
prodrug is an inactive precursor of a drug. The involved temporary chemical modification 
in prodrug can be metabolized in the body in vivo and leave the inherent pharmacological 
properties of the parent drug intact (Saltzman 2001). A conjugation of a drug to a polymer 
was called “polymeric prodrug”, which has led a new era of polymer drug delivery system 
(Pasut and Veronese 2007). Polymeric prodrug has quite a few merits over the precursor 
drug, such as increased solubility, enhanced bioavailability, improved pharmacokinetics, 
ability of targeting and protected activity of protein drug (Khandare and Minko 2006). In 
particular, Polymer-drug conjugation can significantly change biodistribution of the 
therapeutic agent, thus improving its pharmacokinetics (PK) and pharmacodynamics (PD), 
increasing their therapeutic effects and reducing their side effects, as well as provide a 
means to circumvent the multi-drug resistance (MDR), which is caused by overexpression 
of MDR transporter proteins such as p-glycoproteins (p-gp) in the cell membrane that 
mediate unidirectional energy-dependent drug efflux and thus reduce intracellular drug 
levels. The MDR transporter proteins are rich in the liver, kidney, and colon cells. Tumors 
also acquire drug resistance through induction of MDR transport proteins during treatment 
(Harris and Hochhauser 1992; Borst and Schinkel 1996; Schinkel 1997; Gottesman, Fojo 
et al. 2002; Liscovitch and Lavie 2002; Müller, Keck et al. 2003). The medical solution 
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 for MDR is to apply inhibitors of MDR transporters such as cyclosporine A, which may 
also suppress the body immune system and thus cause medical complications. Moreover, 
the inhibitors themselves may have problems in formulation and delivery. The engineering 
solution is thus preferred, which does not use any p-glycoprotein inhibitor. Instead, it 
applies high technologies such as nanotechnology and polymer-drug conjugation, to 
engineering the drugs to avoid being recognized by the p-glycoproteins (Feng and Chien 
2003; Feng 2004; Feng 2006). 
 
Various architectures of polymers have been utilized as carrier to deliver drugs, some of 
which have stepped into clinical development and some have shown promise (Kopeček, 
Kopečková et al. 2001; Duncan 2003). In synthetic polymers, N-(2-
hydroxypropyl)methacrylamine (HPMA) copolymers (Kopeček, Kopečková et al. 2000; 
Chytil, Etrych et al. 2006), Poly(ethylene glycol) (PEG) (Greenwald, Choe et al. 2003; 
Harris and Chess 2003), and poly(L-glutamic acid) (PGA) (Li, Price et al. 1999) have 
been predominantly utilized as the carriers of anticancer drugs such as doxorubicin, 
campothecin and platinates. In particular, PEG is water soluble, biocompatible and 
nontoxic, facilitating its application for conjugation with paclitaxel (Feng, Yuan et al. 
2002), camptothecin (Conover, Greenwald et al. 1998), methotrexate (Riebeseel, 
Biedermann et al. 2002) and doxorubicin (Veronese, Schiavon et al. 2005) to improve 
their water solubility, plasma clearance and biodistribution. 
 
D-α-Tocopheryl Polyethylene glycol 1000 succinate (vitamin E TPGS or simply, TPGS), 
a water-soluble derivative of natural vitamin E, is formed by esterification of vitamin E 
succinate with PEG 1000. Its amphiphilic structure enables it to be an effective emulsifier 
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 and solubilizer (Fischer, Harkin et al. 2002). In our lab, TPGS has been successfully 
applied as a novel emulsifier in preparation of PLGA nanoparticles and as a component of 
a novel biodegradable polymer, PLA-TPGS for nano-carrier of anticancer agents, which 
exhibited high emulsification efficiency, high drug encapsulation efficiency and improved 
cellular uptake, cytotoxicity and therapeutic effects (Feng 2004; Feng 2006). TPGS was 
also demonstrated possessing the ability to enhance the oral bioavailability of 
cyclosporine A, vancomycin hydrochloride and talinolo in animals (Prasad, Puthli et al. 
2003; Bogman, Zysset et al. 2005). Besides, co-administration of TPGS could enhance the 
cytotoxicity of doxorubicin, vinblastine and paclitaxel by the inhibition on p-glycoprotein 
mediated MDR (Dintaman and Silverman 1999).  
 
Doxorubicin, an anthracyclinic antibiotic, is a DNA-interacting chemotherapeutic drug 
(http://en.wikipedia.org/wiki/Doxorubicin; Takakura and Hashida 1995), which is 
effective in treating breast cancer (Bonfante, Ferrari et al. 1986) as well as ovarian (ten 
Bokkel Huinink, van der Burg et al. 1988), prostate (Raghavan, Koczwara et al. 1997), 
cervix (Hoffman, Roberts et al. 1988) and lung cancers (Schuette 2001). However, clinical 
use of doxorubicin is limited because of the short half-life (Al-Shabanah, El-Kashef et al. 
2000) and acute systemic toxicity (Blum and Carter 1974). Additionally, the intracellular 
level of doxorubicin can be reduced by the MDR effects (Krishna and Mayer 2000). This 
triggered us to take the advantages of TPGS and involve it as a carrier by conjugation with 
doxorubicin to enhance the drug’s therapeutic potential in vitro and in vivo as well as to 




 1.2  Objective and Thesis Organization 
This thesis tells a story of TPGS-DOX conjugation for chemotherapy. The novel prodrug, 
TPGS-DOX conjugate, was investigated on drug loading efficiency, conjugate stability, 
drug release property, intracellular uptake, in vitro cytotoxicity and in vivo 
pharmacokinetics and biodistribution. This project provides a novel dose form of 
doxorubicin with improved therapeutic effects, whose methodology can also be utilized in 
other anti-cancer drugs. 
 
The thesis consists of six chapters.  First, an introduction with general background and 
thesis organization are included in chapter 1. Second, chapter 2 gives a comprehensive 
literature review on polymeric-prodrug, highlighting the TPGS advantages in 
chemotherapy. Then chapter 3 is dedicated to the synthesis and characterization of TPGS-
DOX conjugate. TPGS was first activated by succinic anhydride through ring opening 
reaction. Then it was covalently attached to the primary amine group in doxorubicin. The 
resultant product was characterized by FT-IR and NMR for the chemical structure, GPC 
for the molecular weight and the distribution. The doxorubicin content conjugated to 
TPGS was determined by fluorescence detection using microplate reader. The stability of 
the prodrug was investigated in PBS at 4°C. Chapter 4 shows the in vitro results including 
drug release from the conjugate, the intracellular uptake efficiency of the conjugate using 
MCF-7 and C6 cancer cells as in vitro model with comparison of free DOX, and 
cytotoxicity at various drug concentrations. At last, in chapter 5, pharmacokinetics and 
biodistribution via intravenous administration of the TPGS-DOX and free DOX are 
 4






















 2 LITERATURE SURVEY 
 
2.1 Cancer and Cancer Chemotherapy 
2.1.1 Cancer  
Cancer, caused by disordered division of cells, has been seriously threatening human 
health. It is always combined with malignant behavior of these cells, which tend to spread 
by direct invasion into adjacent tissue or metastasis to distant sites 
(http://en.wikipedia.org/wiki/Cancer). Although rapider diagnosis of cancer has been 
achieved than before, many forms are still incurable. According to BBC news, cancer has 
become NO. 1 killer with 135,000 death per year compared to 110,000 from heart disease 
(http://news.bbc.co.uk/1/hi/health/1015657.stm).  
 
So far, the specific mechanisms of formation and spreading of cancer have not been well 
explained. The external effects and internal factors are the most important two 
contributors to the cause of cancer. Radiation, overexposure to certain chemical 
substances, infectious agents, diet and lifestyle can initiate and promote carcinogenesis. In 
particular, the tobacco products can even cause about 80% of all cancers, especially in 
high risk of larynx, oesophagus, pancreas, bladder, kidney, cervix and lung cancers. 
Regarding the internal factors, many theories have been demonstrated. The most important 
seven contributors conclude failure of apoptosis, overactivation of oncogenes, inactivation 
of tumor suppressor genes, cell cycle activation of quiescent cells, acquisition of 
metastatic behavior by malignant cells, disordered responses to cellular growth factors, 
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 and immune system surveillance failure (Hanahan and Weinberg 2000). These factors 
may act together or sequentially, no matter the external or internal ones. 
 
2.1.2 Cancer Treatment 
Cancer cells may break away and grow into a distant point of a normal tissue, which is 
called metastasize. Therefore, tumors are classified to two types, benign and malignant. 
Benign tumors do not spread, which are localized in one part of a body without lethal 
threaten. In contrast, malignant tumors can spread from the original location to other parts 
via the blood or/and the lymphatics, which usually happens in late stage of cancer. 
Different cancer cells have specific propensity in metastasis. Prostate cancer intends to 
spread into bones, while colon cancer prefers liver (Fausto). 
 
Prevention is more active measure than cure to defense against cancer, which is classified 
into primary and secondary type for a patient without and with a history of disease, 
respectively. It was reported that low meat intake and certain coffee consumption are 
associated with the reduced risk of cancer (Ward, Sinha et al. 1997; Sinha, Peters et al. 
2005; Larsson and Wolk 2007). Moreover, some vitamins (Lieberman, Prindiville et al. 
2003), β-carotene (http://www.cancer.gov/cancertopics/factsheet/Prevention/betacarotene) 
and other chemoprevention agents, such as tamoxiten (Vogel, Costantino et al. 2006) and 
finasteride (Baron, Sandler et al. 2006), have been demonstrated to be protective against 
cancer. When prevention fails, cure is necessary. 
 
Cancer can be treated through several methods, the effective ones among which are 
surgery, radiotherapy, chemotherapy, hormone therapy and immunotherapy, although they 
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 possess their own advantages and disadvantages. According to the stage of the cancer and 
the location and grade of the tumor, as well as the condition of the patients, different 
therapy or a combination will be employed. Removing the cancer completely without 
damage to the normal tissue is the ideal solution of the treatment. It can be achieved 
sometimes by surgery, but this is not always feasible, especially when the cancer can 
metastasize to other sites in body. Besides, patients have to suffer from physical pain and 
even the danger of infections. What is worse, it may speed up the growth rate of the 
remaining cancer cells and even cause death by metastatic cancer. The larger excised 
tumor causes the greater possibility of death. Radiation therapy utilizes ironing radiation 
to kill cancer cells and shrink tumors, which can be almost employed into every type of 
solid tumors. It can damage not only the cancer cells but also normal cells. However, the 
normal cells can recover itself after the treatment. As radiotherapy is a localized strategy 
like surgery, it is not effective to the patients suffering metastasis. Hormonal therapy 
employs or blocks certain hormones to inhibit the cancer cell growing, which may cause 
quite a few side effects such as nausea, swelling of limbs and weight gain. Immunotherapy 
is a therapeutic strategy, which induces the patient’s own immune system to fight against 
cancer. Cancer chemotherapy, using chemotherapeutical agents to killing or suppressing 
cancer cells, first succeeded in 1950s and was widely employed in 1960s. However, most 
chemotherapeutic agents cause serious side effects, which limits its application (Feng and 
Chien 2003). Combination of chemotherapy with other strategies is a prominent treatment 
recently in cancer cure.  
 
2.1.3 Cancer Chemotherapy 
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 Chemotherapy sometimes is defined as the use of chemical substances to treat disease 
(http://en.wikipedia.org/wiki/Chemotherapy), which, however, is often toxic and even 
life-threatening. Chemotherapy of cancer utilizes chemotherapeutic agents to control or 
kill cancer cells, usually, via damaging to DNA or RNA of cancer cells 
(http://www.chemocare.com/whatis/cancer_cells_and_chemotherapy.asp). So far, 
hundreds of anti-cancer drugs have been found for clinical application, some of which are 
natural extracts while others are synthetic or semi-synthetic agents. The majority of the 
drugs can be classified into: alkylating agents, antimetabolites, anthracyclines, plant 
alkaloids, topoisomerase inhibitors, monoclonal antibodies, etc. Some drugs perform 
better while working together with other anti-cancer drugs, which is called combination 
chemotherapy. Nanotechnology has been designed and investigated to achieve cancer 
chemotherapy at home (Feng 2004). 
 
2.1.4 Problems in Chemotherapy 
Chemotherapy is an effective and complicated procedure for treating cancer. However, 
anti-cancer drugs not only damage cancer cells, but also affect normal cells, which usually 
leads to serious side effects including hair loss, nausea and vomiting, diarrhea or 
constipation, anemia, malnutrition, memory loss, depression of the immune system, 
hemorrhage, secondary neoplasms, cardiotoxicity, hepatotoxicity, hephrotoxocity, 
ototoxicity and even death (http://en.wikipedia.org/wiki/Chemotherapy). The specific side 
effects are up to what and how much of the chemotherapeutic agent is administrated and 




 Most of anticancer drugs are hydrophobic agents, thus adjuvants are required to make 
them available in clinical use. For example, paclitaxel, a diterpenoid extracted from the 
bark of Pacific yew tree, exhibits a wide anti-cancer spectrum. However, it is too 
hydrophobic with a water solubility ≤0.5 mg/l to be directly administrated into body 
(Mathew, Mejillano et al. 1992). Therefore, Cremophor EL was used as an adjuvant in 
dose form but it causes serious side effects, such as hypersensitivity reactions, 
nephrotoxicity, neurotoxicity and cardiotoxicity (Weiss, Donehower et al. 1990; Li, Price 
et al. 1999). 
 
Moreover, although chemotherapy increasingly succeeds, especially in initial stage, it 
usually becomes less effective in the long-term therapy, which is associated with drug 
resistance. The drug resistance can be due to three mechanisms: pharmacokinetic 
resistance, kinetic resistance and genetic resistance. In a combinational chemotherapy, 
multidrug resistance (MDR) may develop, which is found to be relevant with an 
overexpression of P-glycoprotein (P-gp). P-gp is well known for removal of toxic 
substance in normal function. It effluxes the drugs out of cells by an energy mediated 
unidirectional process. These MDR transporter proteins are rich in the liver, kidney, and 
colon cells and also involved in the various physiological drug barriers such as the 
gastrointestinal (GI) drug barrier for oral chemotherapy, the blood-brain barrier (BBB) for 
brain tumor treatment and the intratumoral barrier for efficient drug delivery in the tumor 
(Harris and Hochhauser 1992; Schinkel 1997; Krishan 2000; Liscovitch and Lavie 2002; 
Müller, Keck et al. 2003). 
 
2.1.5 Chemotherapeutic Engineering 
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 Chemotherapeutic engineering refers to the application and development of chemical 
engineering principles and methodologies for chemotherapy so that better efficacy can be 
achieved with fewer side effects. In order to solve the above problems, effective drug 
delivery system seems as important as the discovery of new drugs, which makes the 
development of chemotherapeutic engineering emergent. In resent decades, the 
development of diversity drug delivery system with improved efficacy but reduced side 
effects became a hot spot in chemotherapy. Numerous drug delivery strategies have been 
intensively investigated, among which microspheres (Couvreur and Puisieux 1993), 
nanoparticles (Couvreur, Roblot-Treupel et al. 1990; Brigger, Dubernet et al. 2002), 
liposomes (Daoud, Hume et al. 1989; Pinto-Alphandary, Andremont et al. 2000), micelles 
(Jones and Leroux 1999), cyclodextrins (Utsuki, Brem et al. 1996), pastes (Li, Price et al. 
1999) and prodrug (Senter, Svensson et al. 1995; Soyez, Schacht et al. 1996; Springer and 
Niculescu-Duvaz 1996; Khandare and Minko 2006) have attracted much attention. 
 
2.2  Polymeric Drug Carrier 
2.2.1 Polymers as Drug Carrier 
In 1974, the discovery of the ability of macromolecules to localize to lysosomes started a 
new era for macromolecules used as drug carriers (De Duve, De Barsy et al. 1974). Since 
1975, when the rationale of polymeric targeted drug delivery was formulated on the basis 
of previous investigations (Ringsdorf 1975), polymers, either natural or synthetic origin, 
have been widely used in drug delivery system.  
 
2.2.1.1  Biodegradable Polymers 
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 The natural polymers, such as collagen, fibrin, alginate, silk, hyaluronic acid and chitosan,  
are abundant and have good biodegradability and biocompatibility, which counteract their 
drawbacks such as immunogenicity, instability and lack of chemical group for 
modification (Duncan and Kopeček 1984). Meanwhile, perhaps synthetic polymers are the 
most widely used materials as growth factor delivery carries, especially for biodegradable 
synthetic polymers, which provide excellent chemical and mechanical properties that 
natural polymers often fail to possess. The frequently used biodegradable polymers 
include poly(ortho esters) (POE), polyanhydride and polyesters. 
 
POE was developed in early 1970s, since when, four families of POE have been indicated 
as shown in Scheme 2-1 (Tomlinson, Heller et al. 2003). The polymer can degrade to a 
diol and a lactone, which will further produce γ-hydroxybutyric acid. The high 
hydrophobic property of the polymer results in the limitation of the amount that water can 
penetrate the polymer. As the erosion rate of the polymers is extremely slow, they can be 
as a compression molded disk in an aqueous environment. More importantly, POE II and 
POE IV have been found to have excellent potential as a delivery system in ocular 




Scheme 2-1 PEO families 
 
Polyanhydrides are a kind of biodegradable polymers in which anhydride bonds connect 
monomer units of the chain. The chemical structure of a polyanhydride molecule with n 
repeating units is shown in scheme 2-2. Water-labile anhydride bonds in polyanhydrides 
give two carboxylic acid groups, which results in easy metabolization and 
biocompatibility. Polyanhydrides consist of three main classes, which are aliphatic, 
unsaturated and aromatic polyanhydrides (Hazra, Golenser et al. 2002). Polyanhydrides 
can degrade uniformly into non-toxic metabolites and thus become useful for controlled 
drug delivery (Hazra, Golenser et al. 2002). Gliade®, made of a polyanhydride wafer 
containing a chemotherapeutic agent, can deliver carmustine to the malignant glioma 
tumor, telling a successful story of polyanhydrides (Mishra and Jain 2000). However, as 
polyanhydrides are quite sensitive to water, some hydrophobic monomers are employed to 




Scheme 2-2 Chemical structure of polyanhydride 
 
Polyesters, which contain the ester functional group in the main chain, have been 
approved by FDA and are widely used as biodegradable polymers. The homo or 
copolymers based on glycolic and lactic acid are significantly common, which have been 
studied for more than 50 years (Lowe 1954; Schneider 1955). Polyglycolide (PGA) is the 
simplest linear, aliphatic polyester. It exhibits somewhat unique solubility, in that the high 
molecular weight form is insoluble in almost all the organic solvents while the low 
molecular weight form is more soluble. On the other hand, PGA is soluble in fluorinated 
solvents, which can be utilized for melt spinning and film preparation (Schmitt 1973). The 
initial application of PGA was limited because of its hydrolytic instability. Recently, PGA 
and its copolymers with lactic acid, ε-caprolacone or trimethylene carbonate are in wide 
use as materials for absorbable sutures and being investigated in biomedical area (Gilding 
and Reed 1979; Middleton and Tipton 1998). Polylactide is thermoplastic, aliphatic 
polyester synthesized from lactide by ring opening polymerization. Due to the chiral 
nature of lactide, there are two optical stereoisomers, poly(L-lactide) (PLLA), poly(D-
lactide) (PDLA) and poly(D,L-lactide) (PDLLA). As PDLLA degrades faster than others 
do, it attracts more attention as a drug delivery system (Conti, Pavanetto et al. 1992). 
Poly(lactic-co-glycolic acid) (PLGA), also a FDA approved copolymer, can be 
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 synthesized by random ring-opening co-polymerization of glycolic acid and lactic acid, 
producing different forms depending on the ratio of two monomers. PLGA can be 
degraded by hydrolysis in water. Besides, PLGA can be dissolved in a wide range of 
common solvents not as the poor solubility of PLA and PGA in organic phase. So far, 
PLA and PLGA are in a dramatically wide application among a variety of biomedical 
devices because of their satisfactory biodegradability, biocompatibility and restorability 
(Holland, Tighe et al. 1986; Van Rensburg, Jooné et al. 1998; Riebeseel, Biedermann et al. 
2002). In addition, poly (ε-caprolactone) (PCL) is another biodegradable polyester, which 
degrades by hydrolysis quite slow in physiological conditions. Thus it is more attractive 
for the preparation of implantable devices and used in controlled release and targeted drug 
delivery (Sinha, Bansal et al. 2004; Zhang, Lee et al. 2007). 
 
 
Scheme 2-3  Chemical structure of some polyesters 
 
2.2.1.2  Polyethylene Glycol 
Poly (ethylene glycol) (PEG, Scheme 2-4) is a unique polyether diol, which has been 
approved by FDA for human intravenous, oral and dermal application. It can be 
manufactured by interaction of ethylene oxide with water, ethylene glycol or ethylene 
glycol oligomers. The ratio of reagents determines the chain length, producing a variety of 
molecular weights of polymers (http://chemindustry.ru/Polyethylene_Glycol.php). 
Initiation of ethylene oxide polymerization using anhydrous alkanols results in a 
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 monoalkyl capped PEG such as methoxy PEG, which is amphiphilic and can dissolve in 
both organic solvents and water. In addition to linear PEG chains, there are also some 
branched PEGs in which two or more PEG chains may be joined through linkers such as 
lysine (Monfardini, Schiavon et al. 1995) and triazine (Abuchowski, van Es et al. 1977). 
Similarly, amphiphilic copolymers have been developed such as PLA-PEG (Ramaswamy, 
Zhang et al. 1997; Nguyen, Allemann et al. 2003; Youk, Lee et al. 2005), PCL-PEG 
(Gyun Shin, Yeon Kim et al. 1998; Kim and Lee 2001; Luo, Tam et al. 2002), PVL-PEG 
(Tomlinson, Heller et al. 2003), PGA-PEG (Smith, Schimpf et al. 1990; Kim, Shin et al. 
1999), etc., which contains both hydrophilic portion and hydrophobic part. Although PEG 
is known to be non-degradable, the non-toxic property (Pang 1993), excellent solubility in 
aqueous solution (Powell 1980), low level of protein or cellular absorption, extremely low 
immunogenicity and antigenicity (Dreborg and Akerblom 1990), and satisfactory 
pharmacokinetic and biodistribution behavior (Yamaoka, Tabata et al. 1994) enable it to 
be an ideal material in pharmaceutical applications (Hooftman, Herman et al. 1996).  
 
 
Scheme 2-4 Chemical structure of PEG 
 
2.2.2 Polymeric Drug Formulations 
2.2.2.1  Paste 
Local administration or direct tumor injection of chemotherapeutic agents has been 
expected by a method that can maximize local drug level in tumor environment but 
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 minimize systemic exposure to normal organs. Chemotherapeutic polymer-paste is one of 
the strategies to reduce local recurrence of disease at tumor site in the surgery. To date, 
paclitaxel-loaded polymeric surgical paste has been designed and well developed. PCL, 
which has low melting range (50-60 °C) and biodegradation lifetime of 6-9 months in vivo 
(Pitt, Gratzl et al. 1981), was employed as the base component. Paclitaxel was added into 
melt PCL and then poured into a prepared mould. The polymer with paclitaxel would 
solidify after cooling down to obtain the paste. In surgical application, paste was melt and 
delivered via injection directly to the tumor resection as a liquid which formed a solid 
conform at surgical wound under body temperature (Winternitz, Jackson et al. 1996). 
Adding mPEG was reported to reduce the onset of the melting temperature by 5-10 °C 
(Winternitz, Jackson et al. 1996), while gelatin, albumin or methylcellulose can speed up 
the release of paclitaxel from the matrix (Dordunoo, Oktaba et al. 1997). Therapeutic drug 
level can be maintained in the region of implanted site but reduced at non-targeting distant 
site. Optimally, all paste formulations showed no great effect on body weight of the 
treated animals, revealing the well tolerated drug dose (Zhang, Jackson et al. 1996). 
However, the brittle and inflexible properties and difficult manipulation limit the further 
development of the paste as the optimal formulations of chemotherapeutic agents. 
 
2.2.2.2  Micelles  
A micelle is an aggregate of surfactant molecules dispersed in a liquid colloid, which 
contains normal phase micelles (oil-phase-water) and inverse phase micelles (water-in-oil). 
When the concentration is higher than the Critical Micelle Concentration (CMC), which is 
the concentration of a monomeric amphiphile the micelle appears (Charman 1992), almost 
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 all of the polymers can formulate to be micelles as a core-shell structure (Fig 2-1) with a 
small particle size (less than 100 nm). Polymeric micelles are manufactured from 
copolymers comprising both hydrophilic and hydrophobic polymers as the core and 
hydrophobic drug can be mainly entrapped into core. For the hydrophobic part, a 
biodegradable polymer such as PLA, PCL, PGA and PLGA is used and for the 
hydrophilic part, PEG is the most used polymer to yield high in vitro stability (Yokoyama, 
Sugiyama et al. 1993). The hydrophobic drug can be loaded in the amphiphiles by dialysis, 
salting out, emulsion and solvent evaporation method. 
 
 
Fig 2-1 Schematic of a micelle 
 
As drug carriers, micelles can provide quite a few obvious advantages. They can solubilize 
poorly soluble drugs and increase drugs’ bioavailability. The size of micelles permits them 
to accumulate in body regions through leaky vasculature. The unique structure makes 
them hardly reactive to blood or tissue components. By attachment via a certain ligand to 
the outer shell, they can result in targeted efficacy. Last but not least, micelles can be 
prepared in large quantities easily and reproducibly (Torchilin 2002). So far, some 
chemotherapeutic agents have been formulated in micelles. Paclitaxel-loaded micelles of 
PEtOx-PCL copolymers was fabricated by dialysis method, which had a size of only 20 
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 nm with a drug loading efficiency of 0.5-7.6%. The micelles showed comparable 
therapeutic efficacy to the commercial paclitaxel in vitro (Cheon Lee, Kim et al. 2003). By 
conjugating folate to PCL-mPEG copolymer, Park et al (Park, Lee et al. 2006) formulated 
the targeted micelles. Doxorubicin-loaded micelles of PEO-P(Asp) (Yokoyama, Kwon et 
al. 1992), PEO-PBLA (Kwon, Naito et al. 1995), PEO-PDLLA (Pişkin, Kaitian et al. 
1995), PAA-PMMA (Inoue, Chen et al. 1998), etc. have been investigated. Although 
micelles can give some improvement in chemotherapy, the instable problems for storage 
became a restriction in further application (Tomlinson, Heller et al. 2003). 
 
2.2.2.3  Liposomes 
Liposomes is a phospholipids spherical vesicle, consisting of an aqueous core surrounded 
by a lipid bilayer or multilayer (Fig 2-2) (http://en.wikipedia.org/wiki/Liposome), usually 
range in size from 0.05 to 5.0 µm. Phospholipids possess a polar head and two 
hydrophobic tails, which is significant to the formulation of bilayer in aqueous solution. 
Due to the unique structure, liposomes can protect and carry hydrophilic drug in aqueous 
core or hydrophobic drug in the lipid layers. The preparation methods may varies 
according to different size and characteristic liposomes, generally including thin-film 
hydration, freeze-drying, detergent dialysis, calcium induced fusion, reverse-phase 
evaporation, sonication and extrusion (Sharma and Sharma 1997).  
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Fig 2-2 Liposomes for drug delivery 
 
Liposomes have attracted much attention in medical application, which is attributed to 
their biocompatibility with cell membranes, capability to protect drug from degradation, 
especially for protein drugs, and ability to add specific targeting ligands on surface (Lee 
and Yuk). As liposomes are manufactured from lipids which are relatively non-toxic, non-
immunogenic, biocompatible and biodegradable, a broad range of water-insoluble drugs 
such as cyclosporine and paclitaxel can be encapsulated. Sharma et al. (Sharma, Mayhew 
et al. 1997) reported that paclitaxel liposomes could deliver drug effectively in body 
system and improve therapeutic index in in vivo model. Traditional liposomes are taken up 
by RES and cleared quickly from blood circulation (Poste, Bucana et al. 1982). 
Cholesterol and PEG modified liposomes significantly impaired such limitations (Wheeler, 
Wong et al. 1994). Moreover, PEGylated liposomes tagged with transferring exhibited 2- 
to 3-fold higher targeting effect than the plain liposomes (Visser, Stevanovic et al. 2005) 
and folate-targeted liposomes showed much higher affinity to tumor cells (Goren, 
Horowitz et al. 2000).  
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 Although liposomes have achieved some improvement in drug delivery system, issues like 
stability, reproducibility, sterilization method, low drug loading efficiency, particle size 
control and short circulation half-life in body are the remaining problems need to be 
solved (Sharma and Sharma 1997). 
 
2.2.2.4  Microspheres 
Microspheres, especially biodegradable polymeric microspheres, have been studied 
extensively. Solvent evaporation and spray drying are two commonly used methods for 
microspheres preparation, as well as hot melt microencapsulation, solvent removal, phase 
inversion microencapsulation (Vasir, Tambwekar et al. 2003). In solvent evaporation 
method, spherical droplets can be formed by dispersing oil soluble monomers in aqueous 
solution (oil in water, O/W) or water soluble monomers in an organic phase (water in oil, 
W/O). Often, a double emulsion is employed, which means the first W/O emulsion in 
which drug is loaded in aqueous phase is then dispersed in another aqueous medium to get 
the final O/W emulsion. Microspheres are able to protect the drug molecules against 
degradation, control their release after administration and facilitate their passage across 
biological barriers. Some researchers have achieved a constant release of drug from the 
polymeric microspheres via a W/O/W double emulsion solvent evaporation method after 
the initial burst (Yang, Chung et al. 2000). Liggins et al (Liggins, D'Amours et al. 2000) 
indicated that microparticles with less than 8 µm may be cleared from the peritoneum into 
the lymph nodes. Recently, poly(ortho-ester) microspheres was made for delivering DNA 
vaccines and tested in vivo (Wang, Ge et al. 2004). However, the relatively large size of 
microspheres may limit its application in some cases such as intravenous delivery.  
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 2.2.2.5  Nanoparticles 
Polymer nanoparticles are microscopic particles with particles size less than 1 µm 
diameter, which have became an attractive area for drug delivery application, especially 
for biodegradable polymeric nanoparticles. Nanoparticles can be used to deliver 
hydrophilic or hydrophobic drugs, proteins, vaccines, biological macromolecules, etc.. 
Nanoparticles can be fabricated by dispersion of polymers and polymerization of 
monomers, which involves solvent extraction/evaporation method, salting-out method, 
dialysis method, supercritical fluid spray technique and nanoprecipitation method (Feng 
and Chien 2003). The most commonly used method is solvent extraction/evaporation, 
which can encapsulate hydrophobic drugs by single emulsion and hydrophilic drugs via 
double emulsion method.  
 
Polymeric nanoparticles have been investigated as potential drug carriers because of their 
unique advantages including providing a controlled release of drugs, targeting drugs to 
tumors, showing available size for intravenous injection, reducing the uptake of drugs to 
RES, improving biodistribution of drugs in body (Kim, Lee et al. 2003). It has been 
indicated that the new-concept chemotherapy by nanoparticles of biodegradable polymers 
can realize personalized chemotherapy with controlled dosage and duration, localized 
chemotherapy by targeting, sustained and controlled chemotherapy with favorable release 
profile of drugs, chemotherapy across biological barriers like GI and BBB, chemotherapy 
at home via oral, nasal or ocular administration (Feng 2004). Innovatively fabricated PLA-
TPGS, PLGA-MMT and PLA-mPEG nanoparticles for paclitaxel formulation exhibited 
great superiority over Taxol and even the PVA-emulsified PLGA nanoparticles (Li, Price 
et al. 1999; Feng and Huang 2001; Feng, Yuan et al. 2002; Riebeseel, Biedermann et al. 
 22
 2002; Mu and Feng 2003; Mu and Feng 2003; Yin Win and Feng 2005; Dong and Feng 
2006; Win and Feng 2006; Zhang and Feng 2006). Besides, targeting (Song, Labhasetwar 
et al. 1998; Nishioka and Yoshino 2001) and multifunctional (Kopelman, Lee Koo et al. 
2005) nanoparticles also become attractive and have been investigated recently. 
Nanoparticles, indeed, showed a promising approach, however, the initial burst and 
incomplete release of the encapsulated molecules in microspheres and nanoparticles, 
particularly for protein, may influence their application (Hong Kee Kim 1999; Kwon, 
Baudys et al. 2001).  
 
2.3 Prodrug 
Polymer-drug conjugation is a major strategy for drug modifications, which manipulates 
therapeutic agents in molecular level in order to increase their biological activity. Such a 
strategy is based on a central assumption that the molecular structure of drugs can be 
modified to make analogous agents, which are chemically distinct from the original 
compound, but produce a similar or even better biological effect. Drug modifications are 
frequently directed to alter the properties of the drug that influence its concentration 
(solubility), its duration of action (stability), or its ability to move between compartments 
in tissues (permeability). Polymer-drug conjugation can modify biodistribution of 
therapeutic agents, thus improving their pharmacokinetics (PK) and pharmacodynamics 
(PD), increasing their therapeutic effects and reducing their side effects, as well as provide 
a means to circumvent the multi-drug resistance (MDR). Prodrug, as the pharmacological 
substance in an inactive form, can be metabolized in the body in vivo into the active 
compound once administered (Saltzman 2001). Polymer-anticancer drug conjugation has 
been intensively investigated in the literature (Khandare and Minko 2006). Some 
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 polymeric prodrugs have stepped into clinical development and several conjugates have 
shown promise (Kopeček, Kopečková et al. 2001; Duncan 2003). 
 
2.3.1 Design and Synthesis of Polymeric Prodrugs 
Polymers have been a hot spot as carriers of drugs over the latest decades, especially 
designed to be polymeric prodrugs. A number of polymeric conjugation methods have 
been investigated since 1955, when peptamin-polyvinylpyrrolidone conjugates with 
improved efficacy was reported (Jactzkewits 1955). In present, there are three major types 
of polymeric prodrugs in use: (a) prodrugs which can be broken down in cells to release 
active agents, (b) prodrugs in combination of more than one substance, (c) prodrugs with 
targeting ability. Generally, an ideal polymeric prodrug was revealed to possess one or 
more of the following components: (a) a polymeric backbone as a carrier, (b) active 
therapeutic agents, (c) appropriate spacers, (d) an imaging substance and (e) a targeting 
molecule (Fig 2-3) (Khandare and Minko 2006). The choice of an appropriate polymer 
and a targeting agent is crucial for the success of a prodrug. The selection of a polymer 
should meet the following criteria: (a) available chemical functional groups to permit 
covalent linkage with drugs or targeting agents, (b) hydrophilic property to ensure water 
solubility, (c) degradability to ensure excretion from the body, (d) biocompatibility to 
avoid immunogenic response, (e) availability in reproduction and administration (Soyez, 
Schacht et al. 1996). The selected polymers can be classified by the origin, chemical 
structure, biodegradability and molecular weight. In addition, modification of a polymer is 
significant, which depends upon the reactive chemical groups in polymer and the 
functional group of the drug. Most of the biomolecules like ligands, peptides, proteins, 
carbohydrates, lipids, polymers, nucleic acid and oligonucleotide possess functional 
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 groups for conjugation or have potential to be activated for further conjugation. According 
to different molecules, a suitable method, process and reagents are, indeed, vital to the 
successful conjugation. The following are some strategies commonly used to obtain a 
polymeric prodrug, mainly regarding the active group and polymer backbone. 
 
 
Fig 2-3 Schematic presentation of (a) polymeric conjugate with targeting moiety and (b) 
hyperbranched polymeric conjugate with targeting and imaging components 
 
2.3.1.1 N-hydroxysuccinimide (NHS) Ester Coupling Method 
An N-hydroxysuccinimide (NHS) ester is perhaps the most common activation chemical 
method for creating reactive acylating agents (Scheme 2-5). Carboxyl groups activated by 
NHS esters show highly reactive to amine nucleophiles. NHS ester derivatives can be 
prepared in nonaqueous condition employing water-insoluble carbodiimides or 
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 condensing agents, or in aqueous media using the water-soluble carbodiimide EDC in situ 
(Hermanson 1996). Due to the high reactivity at physiological pH, NHS is widely utilized 
as an acylating agent and preferred for conjugation with amine terminal compounds (Cruz, 
Iglesias et al. 2001; Luis J. Cruz 2001; Chockalingam, Gadgil et al. 2002; Kajiyama, 
Kobayashi et al. 2004; Cabrita, Abrantes et al. 2005; Natarajan, Xiong et al. 2005).  
However, both hydrolysis and amine reactivity would increase with the increase of pH. 
Thus maintaining high concentrations of protein or other target molecules in the reaction 
is quite necessary. 
 
 
Scheme 2-5 NHS esters compounds react with nucleophiles to release NHS leaving group 
 
2.3.1.2 Carbodiimide Coupling Method 
A carbodiimide is a functional group comprising the formula N=C=N, which is used to 
mediate the formation of an amide or phosphoramidate linkage between a carboxylate and 
an amine or a phosphate and an amine, respectively (Scheme 2-6). The carbodiimides are 
either water-soluble such as EDC or water-insoluble such as DCC and DIC. Water soluble 
carbodiimides can be used for biomacromolecular conjugation in a variety of buffer 
solutions. On the other hand, water-insoluble carbodiimides are preferred for conjugation 
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 of polymers with drugs, imaging agents, targeting agents or other polymers in organic 
solvents (Hermanson 1996). 
 
 
Scheme 2-6 Carbodiimide amide coupling scheme 
 
The most commonly used carbodiimides are N,N'-dicyclohexylcarbodiimide (DCC), N,N'-
diisopropylcarbodiimide (DIC) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) (Scheme 2-7). DCC can bring high yielding amide coupling reaction 
but lead dangerous allergic reaction contacted with skin and the insoluble byproduct N, 
N’-dicyclohexylurea is difficult to be removed completely, which limits its application in 
certain reactions. DIC, as a liquid, can be easily removed by extraction and does not lead 
an allergic reaction, which has been developed as an alternative to DCC. With a favorable 
solubility in water, EDC was widely used in peptide synthesis, protein crosslinking with 
nucleic acids and immunoconjugation (Nakajima and Ikada 1995). 
 
 
Scheme 2-7 Chemical structure of DCC, DIC and EDC, respectively 
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 2.3.1.3 Dextran-prodrug 
Dextran is a complex, branched, natural polysaccharide, which possesses a huge number 
of primary and secondary carbohydrate hydroxyl groups (Scheme 2-8). Thus it can be 
conjugated to drugs and proteins which have active chemical groups either by direct 
conjugation or incorporation of a spacer. Dextran is manufactured from sucrose by certain 
lactic-acid bacteria, the best-known as Leuconostoc Mesenteroides and Streptococcus 
mutans. The homogeneous structure of dextran makes the synthesized conjugates easy to 
characterize and the high water solubility can be restored (Larsen 1989).  
 
 
Scheme 2-8 Chemical structure of dextran 
 
Dextran has been extensively investigated as a polymeric carrier to deliver anticancer 
drugs through conjugation. Mehtyprednisolone and dexamethasome were covalently 
attached to dextran using succinate linker, which showed potential of the dextran prodrug 
in colon-specific delivery of glucocorticoides (McLeod, Friend et al. 1993). 
Methylprednisolone-dextran prodrug (Scheme 2-9) also employed succinic acid as a linker 
and 1,1’-Carbonyldidmidaxole as coupling agent, which achieved controlled hydrolysis 
(Mehvar, Dann et al. 2000). The multiple hydroxyl groups on dextran provide efficient 
functional sites for conjugation. In camptothecin (CPT) analogue-carboxymethyl (CM) 
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 dextran conjugate via Gly-Gly-Gly linker, fluorescein isothiocyanate (FITC) was also 
conjugated to dextran, producing a prodrug with imaging moiety as shown in Scheme 2-
10 (Harada, Murata et al. 2001). A dextran-peptide-methotrexate conjugate with tumor 
targeting capability was reported (Chau, Tan et al. 2004). Due to the conjugated linker, 
Pro-Val-Gly-Leu-Ile-Gly peptide cleavable by matrix metalloproteinase II (MMP-2) and 
IX (MMP-9) that are over expressed in tumors, the conjugate exhibited satisfactory 
stability and high selectivity uptake. 
 
 




Scheme 2-10 Synthesis of FITC-labeled CM dextran 
 
2.3.1.4 N-(2-hydroxypropyl)methacrylamide (HPMA)-prodrug 
N-(2-hydroxypropyl)methacrylamide (HPMA) is a water-soluble, nonimmunogenic, 
synthetic polymer, which has suitability as carriers for drug delivery (Kopecek 1990). 
HPMA copolymers are not biodegradable but are highly biocompatible (Kopeček, 
Kopečková et al. 2000). HPMA homopolymer was designed and manufactured in 
Czechoslovakia as a plasma expander (Kopecek and Bazilova 1973). Many functional 
groups such as charged groups, targeting moieties and drugs can be incorporated into the 
polymer backbone. The spacers in this connection can be either nondegradable or 
degradable. The dipeptide glycylglycin (GG) is always utilized as nondegradable spacer 
(Drobník, Kopeček et al. 1976) while the acid sensitive cis-aconityl bond and the 
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 lysosomal enzyme sensitive tetrapeptide GFLG are employed as degradable spacers 
(Rejmanova, Kopecek et al. 1985).  
 
HPMA copolymers and their conjugates with drugs have become one of the most 
extensively investigated systems. An HPMA copolymer with doxorubicin conjugated with 
the peptidyl linker GFLG exhibited superior cytotoxicity in vitro and successfully 
overcame P-gp mediated drug resistance (Minko, Kopečková et al. 1999; Kopeček, 
Kopečková et al. 2001), which also displayed significant effectiveness in reducing both 
sensitive and resistant tumors in vivo as compared to free DOX (Kopeček, Kopečková et 
al. 2000). Various targeting moieties, such as carbohydrates and antibodies, were attached 
to HPMA copolymer conjugate, which achieved the biorecognizability at the plasma 
membrane (Chytry, Letourneur et al. 1998; Chytil, Etrych et al. 2006). A targeted 
galactosamine containing HPMA copolymer-GFLG-DOX was found to induce dramatic 
tumor associated toxicity (Duncan 1992). These preclinical studies prepared the clinical 
trials of the conjugate, which is available currently. A number of synthetic methods have 
been developed (Scheme 2-11) for antibodies attached to HPMA copolymer conjugates 
via amino groups and oxidized saccharide (Omelyanenko, Kopečková et al. 1996; Chytil, 
Etrych et al. 2006).  
 
2.3.1.5 Dendrimer Conjugates 
Dendrimer, which was defined in the late 1970s and early 1980s, is a new class of 
macromolecules with highly branched, three-dimensional features like the architecture of 
a tree. A typical dendrimer (Scheme 2-12) consists of a multifunctional central core (C), 
branched units (B) and surface groups (S). The branched units represent the repeating 
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 monomer unit which is also called “generations” (Tomalia, Naylor et al. 1990). 
Dendrimers are synthesized from monomers by a step-growth polymerization process, 
including mainly two approaches: divergent (Tomalia 1996) and convergent (Hawker and 
Frechet 1990). The gradual stepwise process of synthesis determines a well defined size 
and structure. The surface characteristics facilitate conjugation of a broad range of 
molecules with different functionality, no matter with drugs, imaging agents or targeting 
moieties (Dufes, Uchegbu et al. 2005). 
 
 
Scheme 2-11 Examples of synthesis of HPMA-drug antibody conjugates 
 
The highly branched structure, the low polydispersity and modifiable end groups assure 
that dendrimer can be used to develop novel drug conjugates. Polyamidoamine (PAMAM) 
dendrimers were the first complete dendrimer family (G=0-7), which are prevalent 
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 nanovehicles for delivery of bioactives. 5-fluorouracil (5FU)-PAMAM conjugates with 
cyclic cores was synthesized using the “time-sequenced propagation” technique, which 
exhibited slow release of the drug (Zhuo, Du et al. 1999). Conjugation of the famous 
anticancer drug cisplatin with PAMAM dendrimers showed slower release, higher 
accumulation in tumors and lower systemic toxicity than free cisplatin (Malik, Evagorou 
et al. 1999). The use of dendrimers as vectors for tumor targeting was also investigated. 
Fréchet et al. fabricated ester-terminated dendrimers containing folic acid, or methotrexate 
(MTX) as drug delivery with tumor cell specificity (Kono, Liu et al. 1999). The conjugate 
of folic acid to the dendrimer utilized coupling of γ-carboxyl group in folic acid to 
hydrazide groups in dendrimers. Dendrimer-peptide conjugates were also reported for the 
development of synthetic vaccines, which had multiple copies of the peptide so that small 
concentrations could result in the required immune response (Tam 1988; McGeary, 
Jablonkai et al. 2001). 
 
 




 2.3.2 PEGylated Drug Conjugation 
PEG possesses an ideal array of properties such as very low toxicity, excellent solubility 
in aqueous media, availability in various molecular weights, extremely immunogenicity 
and antigenicity, ready excretion after administration although non-biodegradable, 
favorable pharmacokinetics and biodistribution, which enable PEG conjugates to become 
classical prodrugs with approval for human use (Goren, Horowitz et al. 2000). Most 
commonly used PEGs for prodrug modification are monomethoxy PEG and di-hydroxyl 
PEG (Scheme 2-13). PEG has limited conjugation capacity since only two terminal 
functional groups can be conjugated to biocomponents. Recently, this limitation has been 
overcome by coupling amino acid to double the number of active groups (Greenwald, 
Choe et al. 2003). To date, a number of strategies have been developed in PEGylated 
conjugates. Anticancer agents have particularly benefited from this technology as well as 
applications to larger proteins. 
 
 
Scheme 2-13 Chemical Structure of (a) monomethoxy-PEG and (b) di-hydroxyl PEG 
 
2.3.2.1 PEGylation of Small Organic Molecules 
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 Water-soluble PEG-drug conjugates are considered to be most promising in drug delivery 
system, especially for delivering hydrophobic drugs with low molecular weight in cancer 
therapy. The most straightforward strategy towards drug-PEG conjugates is relying on 
involvement of the terminal primary hydroxyl groups of PEG to affect the conjugate 
reaction. Direct conjugation of drugs to hydroxyl groups of PEG can be achieved by 
forming ether, carbonate or urethane bonds. With the use of certain spacers like succinate, 
PEG can be used in a larger range of drugs (Goren, Horowitz et al. 2000).  
 
A prodrug strategy using PEG as solubilizing agent has been reported in the case of 
paclitaxel (Greenwald, Gilbert et al. 1996), in which PEGs with different molecular 
weight were employed and compared. Esters with PEG in the α-position were found quite 
effective as linking groups in the design of the prodrug. In vivo test suggested that 
molecular weight play a significant role in solubilizing effect. PEG polymers can be 
modified by small amino acids or other aliphatic chains molecules. For example, The 
antitumor agent 1-β-D arabinofuranosilcytosyne (Ara-C) was covalently attached to linear 
or branched PEG through amino acid spacer for controlled release (Schiavon, Pasut et al. 
2004). Furthermore, the hydroxyl group of PEG was functionalized with a bicarboxylic 
amino acid to form a tetrafunctional derivative (Scheme 2-14), resulting in the conjugates 
with four or eight Ara-C molecules in one PEG chain. Besides, PEG-doxorubicin 
conjugate using amino acid as spacer was investigated (Veronese, Schiavon et al. 2005). 
Although less cytotoxicity in vitro was observed, the prolonged plasma circulation time 




Scheme 2-14 Synthetic schemes of (a) PEG-Ara-C4 and (b) PEG-Ara-C8 conjugates 
 
2.3.2.2 PEGylation of Polypeptide (Peptides and Proteins) 
The conjugation of PEG with the polypeptide (peptides and proteins) has been 
accomplished mainly via reaction with available amino groups, while other reactive sites 
such as histidine and cysteine can be utilized. So as to achieve successful coupling, PEG 
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 must be activated first, which may be done using active ester, active carbonates, 
maleimides or thiazolidine (Greenwald, Choe et al. 2003). 
 
In the pioneering work, PEG-proteins were prepared by conjugation of bovine serum 
albumin (BSA) with mPEG-dichlorotriazine, which exhibited significantly reduced 
immunogenicity and antigenicity (Abuchowski, van Es et al. 1977). R-hirudin, an 
effective antithrombotic peptide, can be modified with two strands of PEG through 
urethane bonds to achieve a dramatically prolonged half-life time with enhanced 
antithrombotic activity and no immunogenicity (Esslinger, Haas et al. 1997). PEGylation 
of granulocyte-colony stimulating factor (G-CSF) contained a single strand of PEG-20000 
covalently bound with the N-terminal amino group of the methionyl moiety of G-CSF 
(Holmes, O'Shaughnessy et al. 2002). The resultant high molecular weight of the prodrug 
significantly reduced renal clearance. Clinical investigation of several other PEGylated 
protein drugs have also been reported, such as IL-2 (Yang, Topalian et al. 1995), growth 
hormone antagonist (Trainer, Drake et al. 2000), and α-interferon (Wang, Youngster et al. 
2000). 
 
2.3.2.3 Targeting PEGylation  
Targeting of the anticancer agents is crucial to the specific sites as it can maximize cancer 
cell death effect and minimize normal cell survive effect. The prodrug that antibody-
targeted biodegradable PEG multi-block attached to N2,N5-diglutamyllysine tripeptide 
with doxorubicin conjugated via acid-sensitive hydrazone bond has been designed and 
synthesized (Ulbrich, Etrych et al. 2002). PEG was first activated with phosgene and N-
hydroxysuccinimide and then interacted with amine group of triethyl ester of tripeptide 
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 N2,N5-diglutamyllysine to get a degradable multi-block polymer, which, later, was 
converted to the polyhydrazide by hydrazinolysis of the ethyl ester with hydrazine hydrate. 
A part of the hydrazide group in polymer was modified with succinimidyl 3-(2-
pyridyldisulfanyl) porpanoate to introduce a pyridyldisulfanyl group for conjugation with 
an activated antibody. DOX was coupled to the remaining hydrazide groups by acid-labile 
hydrazone bonds to the polymer (Scheme 2-15). This prodrug was found having very high 
antitumor activity and significant decrease of non-specific accumulation in the heart, liver 
and lungs. Several other targeting prodrugs, such as DU-257-PEG-KM231 mAb (Suzawa, 
Nagamura et al. 2000) and luteinizing hormone-releasing-hormone-PEG-camptothecin 
(Dharap, Qiu et al. 2003) conjugate, have also been investigated recently. 
 
 
Scheme 2-15 Architecture of multi-block PEG-DOX with targeting antibody conjugated 
 
2.4 Vitamin E TPGS 
2.4.1 Chemistry of Vitamin E TPGS 
D-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS or TPGS) was 
developed in the 1950s as a water-soluble derivative of lipid-soluble natural vitamin E, 
which is prepared by esterification of d-α-tocopheryl succinate (TOS) with polyethylene 
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 glycol 1000. TPGS appears a waxy solid at room temperature and stable in air. The 
molecular weight is around 1542 Da. The thermal degradation and melt temperature are 
199 °C and 38-41 °C, respectively (http://www.eastman.com). TPGS possesses a very low 
critical micelle concentration (CMC) that is 0.02% and can form low viscosity solutions in 
water until the concentration at 20 wt%, beyond which lipid crystalline phases may form 
(Bogman, Zysset et al. 2005).  
 
 
Scheme 2-16 Chemical structure of TPGS: red = hydrophobic vitamin E, green = 
hydrophilic PEG chain, black = succinate linker 
 
TPGS is an amphiphile consisting of lipophilic alkyl tail (TOS) and hydrophilic polar 
head portion (PEG) as shown in Scheme 2-16, which results in the bulky structure and 
large surface area. The hydrophile-lipophile balance (HLB) of TPGS is about 13.2. The 
unique chemical properties of TPGS have suggested its application as a solubilizer, an 
emulsifier, an absorption enhancer, a plasticizer, a water-soluble source of vitamin E, and 
a carrier of hydrophobic drugs. TPGS shows no human toxicity data to date. National 
cancer institute reported that the safety oral dosage of TPGS can be up to 1 g/kg/day 
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 (http://www.eastman.com). The acute oral LD50 of adults is larger than 7 g/kg for either 
TPGS or its moieties, PEG 1000 and TOS (Krasavage and Terhaar 1977). The Japanese 
government’s Ministry of Health, Labour and Welfare approved the application of TPGS 
as a pharmaceutical excipient for oral drug formulations in 2005 
(http://www.inpharmatechnologist.com). 
 
2.4.2 Solubilizer for Water-insoluble Compounds 
It is well known that quite a few drugs, especially anticancer drugs, are poorly water 
soluble. There are many strategies improving solubility and TPGS is a powerful tool to 
solubilize many hydrophobic agents. TPGS was used as solubilizing adjuvant to formulate 
emulsion of an oily composition of several antitumor drugs (Kawata, Ohmura et al. 1986). 
Another early step on the solubilizing effect of TPGS is the work by Ismailos et 
al.(Ismailos, Reppas et al. 1994). The aqueous solubility of cyclosporine A (CyA) at three 
different temperatures (5, 20 and 37 °C) showed 2- to 16-fold increase in the presence of 
various concentrations of TPGS ranging from 0.01 to 0.05 mM. Later, Yu, L. et al (Li, 
Price et al. 1999) reported that TPGS significantly improved solubility of the poorly water 
soluble drug amprenavir, which is a potent HIV protease inhibitor. The solubility linearly 
increased with increasing TPGS concentration through micelle solubilization since no 
increase showed when the concentration of TPGS was below CMC. TPGS was also found 
enhancing the solubility of another selective HIV-1 non-nucleoside reverse transcriptase 
inhibitor, thiocarboxanilide UC-781 (Deferme, Van Gelder et al. 2002). Moreover, a 
dramatic increase in estradiol solubility was found in the aqueous solvent as well as in 
various concentration of ethanol with TPGS (Sheu, Chen et al. 2003). Recently, a new 
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 successful story was documented involving anticancer drug paclitaxel (Varma and 
Panchagnula 2005). Aqueous solubility of paclitaxel was significantly enhanced up to 38 
times by TPGS, revealing TPGS is one of the best semi-solid oral dosage forms for 
taxoids. 
 
2.4.3 Absorption Enhancer 
TPGS has caused much attention on its ability to enhance the absorption of several drugs 
that, otherwise, have poor bioavailability. Sokol et al. (Sokol, Narkewicz et al. 1991), 
Boudreaux et al. (Boudreaux, Hayes et al. 1993) and Chang et al. (Youk, Lee et al. 2005) 
demonstrated that TPGS could enhance absorption of the lipophilic drug cyclosporine, 
which is an immunosuppressive agent to prevent the rejection of transplanted organs. As a 
consequence, the required daily dosage of cyclosporine was significantly reduced to 
maintain therapeutic blood plasma concentration of the drug. TPGS also displayed well as 
an absorption enhancer in amprenavir (Li, Price et al. 1999), which has been already used 
in commercial amprenavir capsules, an agenerase that contains approximately 36 IU of 
vitamin E in 50 mg capsule. Besides many examples of TPGS used for poorly water 
soluble drugs, examples of TPGS used in poorly permeable drugs that are water soluble 
were also reported. Vancomycin hydrochloride, a glycopeptide antibiotic, is water soluble 
but poorly absorbed from the gastrointestinal tract. By introducing TPGS, the Cmax value 
of vancomycin hydrochloride in plasma of rats increased from negligible to over 4.98 
µg/mL (Prasad, Puthli et al. 2003). 
 
2.4.4 Bioavailability Enhancer 
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 As a water-soluble derivative of natural vitamin E, TPGS alone or TPGS/d-α-tocopheryl 
acetate blend provides enhanced bioavailability in not only animals but also some 
populations of human. Quite a few studies supported the use of TPGS to deliver vitamin E 
in human exhibiting fat malabsorption (Traber, Kayden et al. 1986; Sokol, Heubi et al. 
1987; Sokol, Butler-Simon et al. 1993). In the trial, Solol et al. dosed TPGS to 60 children 
with chronic cholestasis, who were unresponsive even to 70-212 IU/kg/day of other oral 
vitamin E forms. All children responded to TPGS at only 25 IU/kg/day oral dose of TPGS 
and neurological function was improved or stabilized in most of patients. The vitamin E 
trial was performed using an emulsified form of tocopheryl acetate, showing the 
concentrations of tocopherols in plasma, erythrocytes and adipose tissues after 
administration were high with TPGS. Thus TPGS provided better bioavailability than the 
other forms. The proposed mechanism explained that the formed TPGS micelles could 
cross from the intestinal lumen to enterocytes. TPGS may be hydrolyzed to release the 
tocopherol which may be transferred into the enterocyte or the whole TPGS micelle could 
be taken up by the enterocyte. Besides, TPGS can also improve the bioavailability of other 
fat soluble vitamins, such as vitamin D (Argao, Heubi et al. 1992).  
 
Not only can TPGS improve the bioavailability of vitamins, it also can enhance the 
bioavailability of pharmacological compounds. Khoo found that by employing TPGS the 
solid dispersion of halofantrine, an important anitmalarial agent, could result in 5-fold 
improvement in absolute oral bioavailability (Khoo, Porter et al. 2000). TPGS enhanced 
bioavailability of cyclosporine A in liver transplant patients and reduced daily dosage to 
40-70% (Sokol, Butler-Simon et al. 1993). Paclitaxel, an antimicrotubule anticancer drug, 
exhibits very poor absorption because of both poor solubility and permeability and thus it 
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 is usually administered via intravenous injection. TPGS enhanced the bioavailability of 
paclitaxel in the in vivo studies due to the increased solubility and permeability. It was 
able to improve not only the bioavailability of oral paclitaxel but also that of other 
biopharmaceutical classification system class II-IV drugs (Varma and Panchagnula 2005). 
 
Regarding the mechanism of TPGS enhancing bioavailability, while Sokol originally 
attributed the reason to micelles formation enhancing solubility, others later provided 
evidence suggesting it could be due to P-glycoprotein (P-gp) inhibition resulting in 
enhanced permeability (Dintaman and Silverman 1999; Wacher, Wong et al. 2002). P-gp 
is primarily expressed on the luminal surface of epithelial cells from certain tissues such 
as intestine, liver, kidney (Thiebaut, Tsuruo et al. 1987). TPGS can play a role as reversal 
agent of P-gp mediated multidrug resistance (MDR) and inhibit P-gp substrate drugs 
transporting. For example, TPGS significantly increased the bioavailability of P-gp 
substrate talinolol in coadministration with talinolol form in vitro cell permeability on 
Caco-2 cells and in vivo intraduodenal perfusion study (Bogman, Zysset et al. 2005). It 
has also been reported that vitamin E was able to protect the human hepatocellular 
carcinoma cells from free-radical induced lipid peroxidation and oxidative DNA damage 
so as to inhibit the MDR phenotype (Fantappiè, Lodovici et al. 2004). Moreover, TPGS 
was found to enhance the cytotoxicity of doxorubicin, vinblastine, paclitaxel and colchine 
that are P-gp substrate agents in G185 cells but not for that of 5-FU which is not P-gp 
substrate (Dintaman and Silverman 1999). TPGS can improve the permeability of a drug 
across cell membranes by inhibiting P-gp, and thus enhance the bioavailability and 
absorption of a drug. 
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 2.4.5 Anticancer Enhancer 
TPGS, a PEG-conjugated derivative of TOS, has been found possessing potent anticancer 
activity since TOS has anticancer properties against wide spectra of cancers such as colon, 
melanomas, breast, brain, lung and prostate cancers (Malafa and Neitzel 2000; Neuzil, 
Weber et al. 2001; Barnett, Fokum et al. 2002; Zhang, Ni et al. 2002; Swettenham, 
Witting et al. 2005). As a comprising moiety, α-tocopherol had the multidrug resistance 
(MDR)-neutralizing activity of the chemosensitizers cyclosporine A, verapamil GF120918, 
clofazimine and a derivative of clofazimine, B669 (Van Rensburg, Jooné et al. 1998). The 
anticancer activity of TOS is related to its apoptosis-inducing characteristics, which 
seemed to be mediated involving the generation of reactive oxygen species (ROS) which 
can damage DNA, proteins and fatty acids in cells leading to apoptotic cell death (Ottino 
and Duncan 1997; Wang, Witting et al. 2005). In xenograft studies, TOS was able to 
suppress tumor growth either alone or in combination with other anticancer agents but 
showed less antiproliferative potent in normal cell types including intestinal epithelial 
cells, prostate cells and hepatocytes than that in tumor cells (Neuzil, Weber et al. 2001; 
Barnett, Fokum et al. 2002; Weber, Lu et al. 2002; Zhang, Ni et al. 2002). However, the 
poor water solubility of TOS limits its therapeutic efficacy. Through the conjugation to 
PEG, the solubility was significantly increased, which was expected to show better 
efficacy. Youk et al. have confirmed that TPGS possessed more effective inhibition on the 
growth of human lung carcinoma cells in in vitro cells and in nude mice than that of TOS 
(Youk, Lee et al. 2005). The superiority of TPGS over TOS in anticancer efficiency was 




 2.4.6 Drug Delivery Applications 
Polymeric drug carriers, by which the drug can be entrapped, encapsulated, adsorbed, 
attached or coupled, open a new era of drug delivery to provide sustained, controlled and 
targeted effects. In drug delivery, TPGS can be used to improve the dissolution rate and 
bioavailability by forming a solid dispersion or a solid solution, controlling or modifying 
the release of the drug, and masking the bitter taste of a drug. Due to the bulky 
amphiphilic structure and large surface area, TPGS is expected to act as a good emulsifier 
or surfactant in drug delivery system, especially in fabricating micro/nanoparticles. As Ke 
et al (Bogman, Zysset et al. 2005) indicated, TPGS can be a good surfactant in oral 
delivery of protein drugs and in synthesis of biodegradable magnetic microspheres. TPGS 
can also be surfactant coating material in fabrication of PLGA nanoparticles by modified 
solvent extraction/evaporation method (Mu, Seow et al. 2004). Mu and Feng demonstrated 
that TPGS acted as a more effective and safer emulsifier for fabrication and 
characterization of polymeric nanoparticles in comparison with traditional PVA 
(Riebeseel, Biedermann et al. 2002). TPGS can achieve far higher emulsification 
efficiency with the amount of 0.015% (w/w) in fabrication whereas 1% PVA is required in 
similar process. Co-polymerizing TPGS with a polymer such as PLA, PLGA or PCL can 
enhance the emulsification efficiency and drug loading capability as demonstrated in the 
studies on microencapsulated paclitaxel (Mu and Feng 2003; Zhang and Feng 2006). The 
in vitro drug release was increased by 2-fold after one day and 3-fold after 31 days for the 
PLGA and PLA/TPGS nanoparticles, respectively. It also showed to tailor the release rate 
via increasing the entrapped drug release (Xie and Wang 2005). Besides, TPGS can be 
used as a good additive in fabricating PLGA nanoparticles and discs for paclitaxel 
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 formulation with up to 80% drug loading efficiency (Wang, Ng et al. 2003; Mu, Teo et al. 
2005). 
 
The further in vitro and in vivo investigation confirmed the great potential of TPGS in 
drug delivery. Feng et al (Feng 2004) demonstrated that TPGS emulsified nanoparticles 
could increase cancer cell mortality and enhance the cellular uptake of Caco-2 cells that 
used as a model of the GI barrier. Nanoparticles coated by TPGS eliminated the acute side 
effects caused by Cremophor EL which is an adjuvant in commercial Taxol. In in vivo PK 
investigation of PLA-TPGS nanoparticles prepared by the dialysis method, 1.8-times 
larger AUC and 11.6-times longer half-life were observed than that of Taxol after i.v. 
administration (Feng 2006). As it is for TPGS emulsified PLGA nanoparticles, 4.9-times 
increased AUC and 2.4-times prolonged therapeutic time in comparison of Taxol after i. v. 
injection were reported (Win and Feng 2006).  
 
Moreover, TPGS displayed promise as a matrix material in nasal delivery. Prepared by the 
combination of double emulsion method and spray drying method, diphtheria taxoid 
loaded PCL/TPGS microspheres exhibited high immune response than that achieved using 
PCL microspheres alone, which showed favorable potential of TPGS as a novel adjuvant 
either alone or with other appropriate delivery materials (Somavarapu, Pandit et al. 2005). 
 
2.5 Doxorubicin 
2.5.1 History  
Doxorubicin, (8s, 10s)-10-(40amino-5hydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-6, 
8, 11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7, 8, 9, 10-tetrahydrotetracene-5, 12-
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 dione, is an anthracycline antibiotic. The history of its discovery can trace back to the 
1950s, when a bright red pigment, later named daunorubicin, was isolated from 
Streptomyces peucetius. The clinical use began in 1960s for treating acute leukemia and 
lymphoma, although fatal cardiac toxicity was recognized in 1967 (Tan, Tasaka et al. 
1967). In 1969, a strain of Streptomyces mutated by N-nitroso-N-methyl urethane 
produced a different, red-colored antibiotic, doxorubicin (Scheme 2-17), which exhibited 
better anticancer activity than daunorubicin but the cardiotoxicity remained (Arcamone, 
Cassinelli et al. 1969). Doxorubicin is one of the most powerful chemotherapeutic drugs 
for the treatment of some leukemias, hodgkin’s lymphoma, as well as cancers of the 




Scheme 2-17 Chemical structure of doxorubicin 
 
2.5.2 Mechanism of Action 
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 Despite doxorubicin has been frequently used in the treatment of numerous human 
malignancies, the exact mechanism of the action is still somewhat unclear. Several 
mechanisms have been proposed and often subject to controversy.  
 
One of the most popular explanations is the capability of doxorubicin to inhibit DNA 
synthesis which may be due to (a) DNA intercalation or inhibition of DNA polymerase 
activity such as Topoisomerase II (Tanaka and Yoshida 1980; Gewirtz 1999), (b) effects 
on signaling issues of growth arrest and p53 function (Kastan, Onyekwere et al. 1991), (c) 
induction of enzymatic or chemically activated DNA adducts (Cullinane, Cutts et al. 1994) 
and DNA cross-linking (Skladanowski and Konopa 1994), (d) interference with DNA 
strand separation and helicase activity (Fornari, Randolph et al. 1994).  
 
Another widely accepted theory is that oxidative stress and the resultant free radicals that 
can lead to direct oxidative injure to DNA are related to doxorubicin action (Gewirtz 1999) 
through two different ways. As for the first way, a doxorubicin semiquinone free radical 
were formed involving some NADPH-dependent reductases and the oxygen, redox 
cycling of adriamycin-derived quinine-semiquinone produced superoxide radicals (Olson 
and Mushlin 1990; Singal, Li et al. 2000). In the other way, doxorubicin free radicals may 
be from the reaction with iron which is non-enzymatic. A Fe2+ doxorubicin free radical 
complex could be produced after a redox reaction of doxorubicin and Fe3+ (De Beer, 
Bottone et al. 2001). Besides, several other mechanisms have also been suggested such as 
alterations in calcium metabolism (Singal and Panagia 1984), and non-physiological 
mechanisms (Gewirtz 1999). 
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 2.5.3 Side Effects and Limitations 
Although doxorubicin is one of most effective chemotherapeutic agents with a wide 
anticancer spectrum, its clinical use is still limited by the serious side effects including 
nausea, vomiting, mild alopecia, palmarplantar erythrodysesthesia (Hand-Foot Syndrome), 
neutropenia, and the most serious one, cardiotoxicity. Doxorubicin can not only cause 
acute cardiovascular chances including hypotension, tachycardia and various arrhythmias 
after minutes intravenous administration but also lead to life-threatening chronic effects 
such as hypotension, tachycardia, cardiac dilation and ventricular failure after several 
weeks or months and even years (Edward, Lefrak et al. 1973; Edward A. Lefrak, tcaron et 
al. 1973; Singal, Deally et al. 1987). The cardiotoxicity confines the cumulative dose of 
DOX to 500-600 mg/m2, which still can be increased for tumor but not for heart (Petit 
2004). On the basis of mechanisms of the action, the cardiotoxicity mechanisms of 
doxorubicin can be attributed to free radical induction, Ca2+ overload accumulation, toxic 
doxorubicin metabolites, production of prostaglandins and platelet activating factor, 
simulation of histamine release, and direct interaction with the actin-myosin contractile 
system (De Beer, Bottone et al. 2001).  
 
Besides these serious irreversible side effects, other drawbacks also limit the clinical use 
of doxorubicin. The multi-drug resistance (MDR) is one of the serious limitations in the 
treatment of cancers through overexpression of MDR transporter proteins such as P-
glycoproteins (P-gp) and multidrug resistance associated protein (MRP). P-gp and MRP 
can be overexpressed in malignant cells, as well as liver, kidney, and colon cells, to pump 
anticancer drugs out of the cancer cells, significantly restricting the intracellular level of 
the drug for effective therapy. Doxorubicin is the very substrate of P-gp and MRP, which 
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In order to impair the side effects and other drawbacks of doxorubicin in chemotherapy, a 
number of studies on the drug formulations have been undertaken. Liposome entrapped 
doxorubicin achieved nigericin-induced “remote release” which resulted in a subsequent 8 
times more effective cytotoxicity than the free drug (Goren, Horowitz et al. 2000). Recent 
report showed that doxorubicin-loaded heparin-liposomes possessed high drug levels for 
up to 64 h after i.v. administration and the half-life was approximately 8.4-fold increased 
than the control liposomes (Han, Lee et al. 2006). Jane et al. (Janes, Fresneau et al. 2001) 
fabricated chitosan nanoparticles as colloidal carriers for doxorubicin, achieving a 
minimal burst release and retained cytotoxicity but induced anti-proliferative activity. 
Later, dextran-doxorubicin conjugate loaded chitosan nanoparticles exhibited enhanced 
therapeutic effect and survival rate in vivo (Mitra, Gaur et al. 2001). With in vitro and in 
vivo work, doxorubicin-loaded polyisohexylcyanoacrylate nanoparticles exhibited 
superiority to overcome the MDR phenotype and lead to a higher anti-tumor efficacy on 
hepatocellular carcinoma that is well known as chemoresistant (Barraud, Merle et al. 
2005). 
 
Numerous investigations involving polymeric prodrug strategy in delivery of doxorubicin 
were also demonstrated and showed favorable results. In early 1995, 
monomethoxypoly(ethylene glycol)-propionic acid N-hydroxysuccinimide ester 
conjugated doxorubicin was designed and studied, which had controlled release via 
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 enzyme dependent hydrolysis, less cytotoxicity in vitro, longer circulation time, greater 
extent in tumor xenografts (Senter, Svensson et al. 1995). Influence of polymer structure 
on drug release, in vitro cytotoxicity, biodistribution and antitumor activity in PEG-
doxorubicin conjugate were extensively investigated by Veronese et al. (Veronese, 
Schiavon et al. 2005). The highest MW PEG showed the longest plasma residence time 
and the greatest targeting but all conjugates were 10-fold less toxic. The doxorubicin 
prodrug N-[4doxorubicin-N-carbonyl (oxymethyl) phenyl] O-β-glucuronyl carbonate 
could achieve completely parent drug activation, 5-fold decreased peek concentration of 
doxorubicin in heart and 10-fold increased AUC in normal tissues than those in tumor 
tissue (Houba, Boven et al. 2001). In the HPMA-based prodrug with doxorubicin attached 
to the carrier via oligopeptide spacer or amide bonds, some of “classic” prodrugs have 
been developed to clinical test (Kopeček, Kopečková et al. 2001; Chytil, Etrych et al. 
2006). Water soluble HPMA copolymer-doxorubicin prodrug with pH-controlled 
activation promisingly displayed high cytostatic activity in vitro and superior anti-tumor 
activity in vivo in comparison of free drug (Chytil, Etrych et al. 2006).  
 
Although hundreds of studies have been reported in formulations of doxorubicin, the 
problems in stability of liposomes, incomplete release of nanoparticles and reduced 







 3 SYNTHESIS AND CHARACTERIZATION OF THE TPGS-DOX 
CONJUGATE 
3.1 Introduction 
TPGS is the derivative of PEG 1000 by conjugation to α-tocopheryl succinate and thus the 
strategy of TPGS-DOX conjugate was similar as PEGylation (Hazra, Golenser et al. 2002). 
As to get the TPGS-DOX conjugate, the terminal hydroxyl group in TPGS was first 
reacted with succinic anhydride through ring-opening polymerization in the presence of 
DMAP as base. Then the carboxyl group needed to be activated by NHS using DCC as 
catalyst. At last, the amine group in DOX interacted with the activated carboxyl group in 
TPGS-SA to get the conjugate, TPGS-DOX. The mechanism for the reaction was shown 
in scheme 3-1 and scheme 3-2. The synthesized conjugate was characterized by fourier 
transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) for the 
molecular structure, gel permeation chromatography (GPC) for the weight-averaged 
molecular weight and polydispersity, microplate reader for drug loading efficiency. The 
stability of the conjugate was studied in PBS at 4 °C. 
 
3.2 Experiment Section 
3.2.1 Materials 
Vitamin E TPGS was obtained from Eastman Chemical Company (TN, USA). 
Doxorubicin hydrochloride, N,N’-Dicyclohexylcarbodiimide (DCC), 
dimethylaminopyridine (DMAP), N-hydroxysuccinimide (NHS), succinic anhydride (SA), 
triethylanmine (TEA), diethyl ether and tetrahydrofuran (THF) were received from Sigma-
Aldrich (St. Louris, MO, USA). All solvents used are HPLC grade, which include 
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 dichloromethane (DCM), dimethyl sulfoxide (DMSO, anhydrous) from Aldrich, and ethyl 
acetate from Merck. All reagent water used in the laboratory was pretreated with Milli-Q 
Plus System (Millipore Corporation, Bredford, USA). 
 
3.2.2 Synthesis of TPGS-DOX 
3.2.2.1 TPGS Succinoylation 
TPGS was activated by succinic anhydride through ring-opening reaction mechanism in 
the presence of DMAP (Sheme 3-1). In brief, 0.77 g (0.5 mmol) TPGS, 0.10 g (1mmol) 
succinic anhydride and 0.12 g (1mmol) DMAP were mixed and heated at 100 °C under 
nitrogen atmosphere for 24 h (Hazra, Golenser et al. 2002). The mixture was cooled to 
room temperature, taken up in 5.0 mL cold DCM, filtered to remove excessive succinic 
anhydride and then precipitated in 100 mL diethyl ether at -10 °C overnight. The white 
precipitate was filtered and dried in vacuum to obtain TPGS succinate reagent with a yield 
of 90%. To synthesize TPGS-SA as a precursor polymer for DOX conjugation, TPGS was 
succinoylated with an excess of succinic anhydride because complete succinoylation is 






























Scheme 3-1 Scheme of TPGS succinoylation 
 
3.2.2.2 TPGS-DOX Conjugation 
The succinoylated TPGS (191.3 mg, 0.12 mmol) was reacted with DOX·HCl (102.5 mg, 
0.18 mmol) with the presence of DCC (74.2 mg, 0.36 mmol), NHS (41.4 mg, 0.36 mmol) 
and TEA (50 µL, 0.36 mmol ) in DMSO at room temperature under nitrogen atmosphere 
for 24 h. In this process, the reaction can be separated into two steps. First, TPGS-SA was 
esterized with NHS using DCC as coupling agent. Then the TPGS-NHS was interacted 
with DOX to get the conjugate. The product was filtered to remove N,N-dicyclohexylurea 
(DCU) and then dialyzed in DMSO for 24 h to remove excess reagents and unconjugated 
DOX, and further dialyzed against Millipore water for 24 h to remove DMSO. The 
resultant solution was freeze-dried to get the red powder with a yield of 83% and a purity 































































Scheme 3-2 Scheme of TPGS-DOX conjugation 
 
3.2.3 Characterization of TPGS-DOX Conjugate  
3.2.3.1 FT-IR 
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 The chemical structure of TPGS-DOX was investigated by Fourier Transform Infrared 
Spectroscopy (FT-IR) (Shimadzu, Japan). The FT-IR samples were prepared by mixing 
99% KBr with 1% conjugate and then pressing to be a transparent tablet. 
 
3.2.3.2 1H NMR  
The molecular structure of TPGS-SA and TPGS-DOX were further confirmed by 1H 
Nuclear Magnetic Resonance Spectroscopy (NMR) in DMSO-d6 at 300 MHz (Bruker 
ACF300). 
 
3.2.3.3 GPC  
The molecular weight and the polydispersity of the conjugate were determined using gel 
permeation chromatography (GPC, Aglient 1000 series GPC analysis system with RI-
G1362A refractive index detector). Agilent PL gel 5 µm mixed-C 300×7.5 mm column 
was employed, which was eluted by THF as a mobile phase at a flow rate of 1mL/min. 
The injection volume was 100 µL of sample solution with a concentration at 1 mg/mL in 
mobile phase. Molecular weight of the conjugate was calculated using a series of 
Polystyrene standards (Mw: 640, 7150, 111400, 1997000).  
 
3.2.3.4 Drug Conjugate Efficiency 
The DOX content conjugated to TPGS was measured using microplate reader (GENios, 
Tean, Switzerland) in DMSO with fluorescence detection at λex=480 nm and λem=560nm. 
A standard curve was generated by using free DOX at concentration range of 100 ng/mL - 
500 µg/mL in DMSO. 
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3.2.3.5 Stability of the Conjugate 
The stability of the conjugate was determined as follows. Five mg prodrug was suspended 
in 5 mL PBS buffer (10 mM, pH 7.8) and sealed in a dialysis bag (M.W. cutoff: 1,000). 
The dialysis bag was incubated in 20 mL PBS buffer at 4oC. The released DOX in the 
incubation medium was collected at the designated time intervals and analyzed at 480 nm 
fluorescence. 
 
3.3  Results and Discussion 
3.3.1 FT-IR Spectra 
The spectra of DOX, TPGS and TPGS-DOX are shown in Fig 3-1. The FT-IR spectrum of 
doxorubicin in Fig 3-1 exhibits multiple peaks at 3346, 2940, 2354, 1617, 1416 and 1072 
cm-1, which corresponded to the different quinine and ketone carbonyls in DOX. However, 
it cannot be delineated the specific bonds between specific quinine and ketone because 
they both have carbonyl groups. The peaks at 872 and 806 cm-1 corresponded to the wag 
of primary amine NH2 and deformation of N-H bonds, respectively. As for the spectrum 
of TPGS, the peak at 1740 cm-1 was due to the carbonyl group. The peak region of 2870-
3000 cm-1 was generated by the aliphatic (C-H) functional group. From the spectrum of 
TPGS-DOX conjugate, we can find that the peak at 872 and 806 cm-1 had disappeared and 
instead, a peak at 1430 cm-1 turned up standing for N-H deformation in secondary amine 
structure, which confirmed the secondary amine linkage between –COOH group in TPGS 
and –NH2 group in doxorubicin. The conjugate showed significant signal from TPGS but 




Fig 3-1 FT-IR spectra of DOX (red line), TPGS (purple line) and TPGS-DOX (blue line) 
 
3.3.2 1H NMR Spectra 
1H NMR employing DMSO-d6 as solvent was used to confirm the product identity. The 
spectrum of TPGS-SA demonstrated that the succinoyl methylene (CH2) gave signals at 
2.3-2.4 ppm in comparison with that of TPGS as shown in Fig 3-2a, b. The typical 1H 
NMR spectra of DOX and TPGS-DOX conjugate are shown in Fig 3-2c, d. The spectrum 
of DOX exhibited typical peaks at 3.99 ppm (H3C-O-C-1), 5.45 ppm (HC-1’), 7.69 ppm 
(HC-3) and 7.91 ppm (HC-2 and HC-4). The spectrum of TPGS showed an intense peak 
at 3.51 ppm, which was the characteristic of methylene protons of the PEG part of TPGS. 
The spectrum of TPGS-DOX contained both signals originating from DOX and TPGS, 
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 but with much weaker intensity than the signals of DOX. This may be due to the small 
molecular weight of DOX compared with that of TPGS. 
 
3.3.3 GPC Results 
The TPGS-DOX conjugate was analyzed by gel permeation chromatography (GPC) as 
shown in Fig 3-3. The prodrug was eluted earlier than the unconjugated TPGS, which 
demonstrated that DOX was conjugated to TPGS. The molecular weight of the conjugate 
and the TPGS was 2,655 and 2,221, respectively. The ratio of the weight-averaged over 
the-number molecular weight of the conjugate (Mw/Mn) was 1.16. The slight increase was 
due to the DOX conjugation and the loss of the low molecular weight TPGS fraction in 
the purification process. By GPC analysis, it can be confirmed that the TPGS-DOX 
conjugate was synthesized successfully and the product was not a physical mixture of 






Fig 3-2 1H NMR spectra of (a) TPGS, (b) TPGS-SA, (c) DOX, (d) TPGS-DOX with the 
























3.3.4 Drug Loading Capacity 
The DOX content in the TPGS-DOX conjugate was determined to be 8.0% by the 
microplate reader using fluorescence at 480 nm. It is important to note that the DOX 
loading capacity (8.0 wt%) of our TPGS-DOX conjugate is as favorable as that for other 
polymer–DOX conjugates being tested clinically, which is, for example, 8.5 wt% for 
HPMA copolymer-DOX conjugate (Vasey, Kaye et al. 1999), 2.5-5 wt% for PEG-DOX 
conjugate (Rodrigues, Beyer et al. 1999), and 5-16 wt% for PGA-DOX conjugate (Hoes, 
Grootoonk et al. 1993). The satisfactory drug loading capacity of TPGS-DOX conjugate 
facilitates its clinical test in future. 
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 3.3.5 In Vitro Stability 
As the stability regards, the result is also satisfactory. It was found that after 24 h in PBS 
buffer (pH 7.8) at 4 oC, the conjugate underwent only a small amount of hydrolysis 
resulting in the release of approximately 2% of the bound DOX. Even after 5 months, only 
12% of the conjugated drug was released from the conjugate. Therefore, most of the DOX 
can be stably attached to the polymer under the test conditions, which enables its 
relatively long time storage. 
 
3.4 Conclusions 
TPGS-DOX conjugate were synthesized via the interaction between the carboxyl group in 
TPGS-SA and the primary amine group in DOX in the presence of the coupling agent. 
The conjugate was characterized by FT-IR, 1H NMR and GPC to detect the molecular 
structure, molecular weight and polydispersity, in which results confirmed the successful 
synthesis of the conjugate. The TPGS-DOX also exhibited favorable drug loading 
capacity in comparison with the clinical prodrug candidate. Besides, the in vitro stability 









 4 IN VITRO STUDIES ON DRUG RELEASE KINETICS, 




The release of the drug from the polymeric carrier is important for its further therapeutic 
function. Usually, the release of drug can be mediated by simple hydrolysis. In this study, 
the drug release was studied in PBS at 37 oC with different pH values. It is demonstrated 
that TPGS can enhance the intracellular cell uptake of human colon carcinoma cells (Win 
and Feng 2006). As for the in vitro study, MCF-7 breast adenocarcinoma cells and C6 
glioma cells were utilized as in vitro model. The TPGS-DOX may also enhance the 
cellular uptake of the doxorubicin through escaping from P-gp drug efflux pump, which 
was investigated in this chapter. Cellular uptake of the conjugate was further visualized by 
confocal laser scanning microscopy (CLSM) to indicate the intracellular distribution. 
Cancer cell viability of TPGS-DOX conjugate was quantitatively determined by MTT 
method. All the experiments were conducted in close comparison with the pristine DOX. 
 
4.2 Materials and Methods 
4.2.1 Materials 
3-(4,5-cimethylthiazol-z-yl)-2,5-diphenyl chloroformate (MTT),  phosphate buffered 
saline (PBS), Dulbecco’s Modified Eagel Medium (DMEM), penicillin-streptomycin 
solution, Trypsin-EDTA and Triton® X-100 were obtained from Sigma-Aldrich (St. 
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 Louris, MO, USA). Fetal bovine serum (FBS) was received from Gibco (Life 
Technologies, AG, Switzerland). 
 
4.2.2 In Vitro Drug Release 
The rate of DOX release from the conjugate was investigated in 10 mM PBS at pH 3.0, 
5.0 and 7.4 at 37 oC, respectively. The conjugate solution of 200 µg/mL equivalent DOX 
concentration was placed in a dialysis bag (MW cutoff: 1,000) and incubated in 20 mL of 
the PBS solution with gentle shaking. The incubated solution was collected at designated 
time points and equal volume of fresh medium was compensated. The released DOX 
amount was determined by fluorescence detection at 480 nm. 
 
4.2.3 Cell Culture 
MCF-7 breast adenocarcinoma cells and C6 glioma cells (American Type Culture 
Collection, VA) were employed as in vitro models. The cells were cultured in the DMEM 
medium supplemented with 10% FBS, 1% penicillin-streptomycin solution, and incubated 
in SANYO CO2 incubator at 37oC in humidified environment of 5.0% CO2. The medium 
was replenished every other day until confluence was achieved. The cells were then 
washed with PBS and harvested with 0.125% Trypsin-EDTA solution. 
 
4.2.4 In Vitro Cell Uptake Efficiency 
In the quantitative investigation, MCF-7 and C6 cells were seeded in 96-well black plates 
(Costar, IL, USA) at a density of 3×104 cells/well. When the cells reached about 80% 
confluence, as for the investigation of comparison of the prodrug and the free drug, the 
medium was replaced by 100 µL TPGS-DOX or free DOX solution in medium at 1 
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 µg/mL DOX concentration for 0.5, 1.5, 4, 6 h, respectively. Regarding the concentration 
related effects in cell uptake, the medium was replaced by 100 µL TPGS-DOX or free 
DOX at 1, 5, 25 µg/mL DOX for 4 h. For each sample, six wells were seeded for positive 
control and six wells for sample wells. At the designated time interval, the sample wells 
were washed three times with 50 µL PBS and then added 100 µL culture medium. All the 
wells were then lysed by 50 µL 0.5% Triton 100 in 0.2 M NaOH. The fluorescence 
intensity of each sample was detected by the microplate reader (Tecan, Männedorf, 
Switzerland, λex = 480 nm, λem = 560 nm). Cellular uptake efficiency was expressed as the 
percentage of the fluorescence associated with the cell vs that present in the positive 
control (Zhang, Lee et al. 2007).  
 
4.2.5 Confocal Laser Scanning Microscopy 
As for the qualitative investigation, MCF-7 and C6 cells were incubated with TPGS-DOX 
conjugate or free DOX medium solution at 1 µg/mL DOX concentration under 37oC for 4 
h. Then the cells were rinsed with cold PBS for three times, fixed by 75% ethanol for 20 
min, and then washed twice by PBS. Finally, the cells were mounted by the mounting 
medium (DAKO® Fluorescent Mounting Medium) and observed under confocal laser 
scanning microscopy (Zeiss LSM 510, Germany). 
 
4.2.6 In Vitro Cytotoxicity 
MCF-7 and C6 cells were seeded at a density of 5×103 cells/well in 96-well plates (Costar, 
IL, USA) and incubated for 24 h. The medium was then replaced by the free DOX or 
TPGS-DOX conjugate at various drug concentrations from 0.002 to 100 µM in the 
medium. The cell viability was determined by the MTT assay. At the designated time 
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 intervals 24, 48, 72 h, the medium was removed and the wells were washed twice with 
PBS. Ten percent MTT (5 mg/mL in PBS) in medium was added and the cells were 
incubated for 3-4 h. After that, the precipitant was dissolved in 100 µL isopropanol and 
each well was finally analyzed by the microplate reader with absorbance detection at 570 
nm. The cell viability was figured out using the following formula, 
Cell viability (%) = (Abss  / Absc) × 100 
where Abss stands for the fluorescent absorbance of the wells of the drug samples and 
Absc is that of the wells of the culture medium used as positive control.  
 
The MCF-7 and C6 cell viability of TPGS was also investigated at various concentrations 




Statistical analysis was conducted by using the student’s t-test with p<0.05 as significant 
difference. 
 
4.3 Results and Discussion 
4.3.1 In Vitro Drug Release 
In vitro release of the drug from TPGS-DOX conjugate was measured at various pH 
conditions. As shown in Fig 4-1, the DOX release showed no dramatic initial burst. It was, 
however, significantly pH-dependent. The lower the pH value was, the faster the drug 
released. Specifically, the drug released rapidly from the conjugate at pH 3.0, reaching 
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 52.3±2.4% after 48 h and almost 100% within 10 days, whereas the DOX release at pH 
5.0 was much slower, implying 27.1±1.4% and 43.6±2.8% in the same period, 
respectively (p<0.01). As desired, only a small amount of drug (12.6±0.2%) was released 
at pH 7.4 over the observed period. 
 
The release of the free active drug from the carrier may play an important role, which is 
considered as a prerequisite for the conjugate bearing drugs bound to the polymer via 
degradable bonds. In most cases, release of anticancer drugs from the polymer carrier is 
mediated by simple hydrolysis (Maeda, Seymore et al. 1992; Takakura and Hashida 1995). 
The free DOX is known to be stable in the pH range 3.0-6.5 (Vigevani and Williamson 
1980). In the TPGS-DOX conjugate, DOX might be released from the conjugate by 
hydrolysis, which was sensitive to pH value. This effect may be involved to speed up the 
drug release inside cancer cells as the proton concentration in lysosomes is usually at least 
100-fold higher (<pH 5.0) than the outside of the cells (pH 7.4). The release profile 
confirmed that the linkage was labile under mild acidic conditions anticipating endosomal 
environment and sufficiently stable in blood circulation (pH 7.4) to allow the transport of 






























Fig 4-1 Release of DOX from TPGS-DOX conjugate incubated in phosphate buffer at 37 
oC (mean ± SD and n=3) 
 
 
4.3.2 In Vitro Cellular Uptake 
It is known that the cellular internalization and sustained retention of the drug play 
significant role in therapeutic effects. The in vitro investigation can give preliminary 
information of the priority of the prodrug over the parent drug despite it cannot make sure 
the definitely same results in vivo. 
 
Fig 4-2 shows (a) MCF-7 and (b) C6 cellular uptake efficiency of the TPGS-DOX 
conjugate compared to the pristine DOX after 0.5, 1.5, 4, 6 h cell culture. The same 1 
µg/mL DOX concentration in the culture medium was applied in the experiment. It can be 
seen from Fig 4-2 that the TPGS-DOX conjugate exhibited enhanced cellular uptake of 
1.7- (69.8±8.8% for TPGS-DOX vs 39.9±2.4% for DOX), 1.3- (75.5±6.0% for TPGS-
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 DOX vs 56.7±3.4% for DOX), 1.2- (78.6±6.8% for TPGS-DOX vs 64.2±6.4% for DOX), 
1.2-fold (86.0±5.1% for TPGS-DOX vs 72.5±2.0% for DOX) (p<0.05) for the MCF-7 
cells and that of 5.4- (27.0±1.7% for TPGS-DOX vs 4.93±0.1% for DOX) , 5.9- 
(34.0±2.7% for TPGS-DOX vs 5.70±0.2% for DOX), 1.3- (48.7±7.8% for TPGS-DOX vs 
37.4±5.4% for DOX), 1.1-fold (73.6±1.8% for TPGS-DOX vs 69.7±3.5% for DOX) 
(p<0.05) for the C6 cells after 0.5, 1.5, 4, 6 h cell culture, respectively, in comparison with 
pristine DOX. Besides, the absolute cellular uptake efficiency for the MCF-7 cells is 
generally higher than that for the C6 cells. Almost all of the TPGS-DOX samples in MCF-
7 cells displayed the cell uptake efficiency above 70%, whereas most of the TPGS-DOX 






































































Fig 4-2 (a) MCF-7 and (b) C6 cell uptake efficiency cultured with the pristine DOX or the 
TPGS-DOX for 0.5, 1, 4, 6  h respectively at equivalent drug concentration 1 µg/mL 
(mean ± SD and n=6) 
 
 
Fig 4-3 exhibits the cellular uptake efficiency of TPGS-DOX and free DOX in (a) MCF-7 
and (b) C6 cells, respectively, which was assayed upon 4 h culture with different drug 
concentration. It is obvious that both prodrug and free drug showed decreased cellular 
uptake efficiency when the equivalent drug concentration was increased from 1 µg/mL to 
25 µg/mL. The trend was found in both MCF-7 and C6 cancer cells, which indicated a 
saturated and limited property of cellular uptake of the prodrug and free drug. Similarly as 
the above results, the cell uptake of TPGS-DOX was higher than that of DOX, no mater in 
which cell line and at which drug concentration. The cell uptake was enhanced to 1.2- 
(78.6±6.8% vs 64.2±6.4%), 1.1- (30.6±1.2% vs 27.5±0.3%), 1.1-fold (26.4±0.6% vs 
24.0±2.0%) (p<0.05) in MCF-7 cells and 1.3- (48.7±7.8% vs 37.4±5.4%), 1.4- (39.5±8.0% 
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 vs 28.9±4.9%), 1.1-fold (25.4±6.9% vs 323.5±4.2%) (p<0.05) in C6 cells by TPGS-DOX 




































































Fig 4-3 Cell uptake of the TPGS-DOX and DOX in (a) MCF-7 and (b) C6 cells after 4 h 




The difference of the cell uptake between the conjugate and the free drug may be due to 
the MDR effect, which is a major cause for the failure of anti-cancer chemotherapy 
because of the overexpression of MDR transporter proteins such as P-glycoprotein (P-gp) 
that mediate unidirectional energy-dependent drug efflux and thus reduce intracellular 
drug levels.  As the free DOX regards, most of the molecules would be effluxed out by P-
gp pump proteins except those that could bind to DNA after entering the cells (Zhang and 
Feng 2006). In contrast, the TPGS has inhibitory effect on the P-gp, the multidrug 
resistance transporter, so that less drug would thus be pumped out of the cells, resulting in 
a higher cell uptake efficiency (Dintaman and Silverman 1999). 
 
4.3.3 Confocal Laser Scanning Microscopy 
The cellular uptake of TPGS-DOX conjugate was further investigated by confocal laser 
scanning microscope (CLSM).  The four pictures in Fig 4-4 show respectively the 
confocal laser scanning microscopy of MCF-7 cancer cells after 4 h incubation with (a) 
the pristine drug DOX and (b) with the TPGS-DOX conjugate, and that of C6 cancer cells 
with (c) the DOX and (d) the TPGS-DOX conjugate at the same 1 µg/mL DOX 
concentration. The cells in (b) and (d) had become unhealthy, which was agreeable with 
the cellular uptake results as shown in Fig 4-3 and thus confirmed the advantages of the 
TPGS-DOX conjugate over the original DOX. Moreover, it can be seen from Fig 4-4 that 
the free DOX was mainly distributed within the nucleus (Fig 4-4 a, c) in both cancer cells, 
while the conjugate could be observed around the nucleus resulting a broad intracellular 
distribution in the cytoplasm (Fig 4-4 b, d). The change of intracellular distribution of the 
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 drug by TPGS conjugation may play an important role, which is similar to that reported in 
the literature for the PEG-DOX conjugate (Rodrigues, Beyer et al. 1999). This result 
reveals that the conjugate may deliver the drug into the cells in a different way from the 
simple diffusion of the free drug in the cells. Besides intercalation with DNA, the 












Fig 4-4 Confocal laser scanning microscopy (CLSM) of MCF-7 cells after 4 h incubation 
with (a) the pristine drug DOX and (b) with the TPGS-DOX conjugate, and that of C6 




4.3.4 In Vitro Cytotoxicity 
The MCF-7 and the C6 cell line were employed as in vitro models to investigate the 
cytotoxicity of the TPGS-DOX conjugate in close comparison with the pristine DOX as a 
positive control. Fig 4-5 shows the cellular viability of (a) MCF-7 cells and (b) C6 cells 
after 24, 48, 72 h culture respectively with the TPGS-DOX conjugate in comparison with 
that of the pristine DOX at various DOX concentrations. It can be seen from the two 
graphs that the TPGS-DOX conjugate exhibited significantly higher cytotoxicity 
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 (equivalent lower cell viability) at low drug concentration (p<0.05) or at least, comparable 
cytotoxicity at high drug concentration in comparison with the pristine DOX. This 
advantage became more significant for longer time cell culture.  
 
As the cytotoxicity of TPGS regards, no significant cell killing ability was found for C6 
cancer cells and only slight cytotoxicity was observed for MCF-7 cancer cells (Fig 4-6). 
However, the cell viability of TPGS in each sampling point is above 50%. This means that 
the enhanced cytotoxicity of the TPGS-DOX came from the conjugation strategy but not 




















































Fig 4-5 Cellular viability of (a) MCF-7 breast cancer cells and (b) C6 glioma cells after 24, 
48, 72 h culture with  the DOX-TPGS conjugate respectively in comparison with that of 
the pristine DOX at various equivalent DOX concentrations (mean ± SD and n=6) 
 
It is obvious that the cell viability decreased with increase of the drug concentration. The 
IC50 value, i.e. the drug concentration at which 50% cells have been killed in a given 
period,  can thus be used as an quantitative index to evaluate in vitro the therapeutic 
effects of a drug in that given period. Table 4-1 lists the IC50 values of the TPGS-DOX 
conjugate and the free drug DOX after 24, 48, 72 h cell culture, respectively. It can be 
concluded from this Table that the TPGS-DOX conjugate achieved much lower IC50 
values than the free drug DOX in all the cases for MCF-7 and C6 cells at various periods. 
The trends became more significant for longer time incubation. The IC50 of the MCF-7 
cells was found to be 52.3, 0.357, 0.00916 µM for the TPGS-DOX conjugate vs 76.7, 
0.1173, 0.0577 µM for the pristine drug DOX, which implied 31.8, 69.6, 84.1% more 
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 effective in vitro, after 24, 48, 72 h culture, respectively. The IC50 of C6 cells was found to 
be 20.8, 0.0712, 0.00468 µM for the TPGS-DOX conjugate vs 37.1, 0.568, 0.00810 µM 
for the pristine drug DOX, which implied 43.9, 87.7, 42.2% more effective in vitro, after 
24, 48, 72 h culture, respectively.  
 
 
Table 4-1 IC50 values (in equivalent µM DOX level) of MCF-7 and C6 cancer cells 
cultured with the TPGS-DOX conjugate vs the pristine DOX in 24, 48, 72 h 
 
IC50 (µM) 
C6 cells MCF-7 cells 
Incubation 
time (h) DOX TPGS-DOX DOX TPGS-DOX 
24 37.1 20.8 76.7 52.3 
48 0.568 0.0712 0.1173 0.0357 
72 0.00810 0.00468 0.0577 0.00916 
 
 
It is thus evidenced at least in vitro that the TPGS conjugation greatly enhanced the 
therapeutic effects of doxorubicin. What’s more, the IC50 values of TPGS in both cell lines 
were larger than 400 µM. It is thus evidenced, once again, that the enhanced cytotoxicity 






















Fig 4-6 Cellular viability of MCF-7 breast cancer cells and C6 glioma cells after 24, 48, 
72 h culture with TPGS respectively at various equivalent concentrations in the conjugate 
(mean ± SD and n=6) 
 
 
It is well known that polymer-drug conjugation usually results in higher IC50 values in 
vitro than the parent drug due to changes caused in cellular pharmacokinetics such as 
slower endocytic capture compared with rapid transmembrane passage of the parent drug 
(Duncan 1992). The DBM2-PEG4000-S-PEG3000-GFLG-DOX conjugate was found 10-20-
fold less toxic than free DOX against B16F10 murine melanoma in vitro (Andersson, 
Davies et al. 2005). The PEG-DOX conjugates were demonstrated over 40-fold less toxic 
than the free DOX toward H2981 human lung adenocarcinoma cells (Senter, Svensson et 
al. 1995). On the contrary, our TPGS-DOX conjugate showed much lower IC50 values in 
comparison with the parent drug, which indicated that TPGS-DOX is promising in 
 78
 enhancing the therapeutic effects of the conjugated drug. Although TPGS itself showed 
slight cytotoxicity for MCF-7 cells, its IC50 is much larger than that of the DOX and the 
TPGS-DOX. This proves that the enhanced therapeutic effect mainly comes from the 
conjugation strategy but not from the carrier itself. This great advantage may be attributed 
to the unique pharmaceutical properties of TPGS, which is also involved after the 
conjugation. First, it can induce apoptosis, a cell death mechanism shared by the majority 
of anticancer drug, to exert anti-tumor effect (Porta 2004; Youk, Lee et al. 2005). Second, 
TPGS is able to inhibit the MDR effect caused by P-gp efflux pump. The mechanism of 
TPGS-DOX internalization may deliver DOX to intracellular compartments that are less 
accessible to the P-gp. In this respect, the result of the cytotoxicity experiment was 
consistent with that of the cellular uptake. Last but not least, as TPGS possesses great 
ROS (reactive oxygen species)-generating ability (Youk, Lee et al. 2005), it is plausible 
that TPGS shows selective cytotoxicity to facilitate cytotoxicity of the conjugated drug 




In vitro release of DOX from the conjugate was found pH dependent with no significant 
initial burst. TPGS-DOX conjugate displayed higher cellular uptake efficiency than that of 
free DOX, no matter the drug concentration, incubation time nor MCF-7 or C6 cancer 
cells. The in vitro confocal laser scanning microscope imaging confirmed that the TPGS-
DOX conjugate was found distributed around the nucleus and cytoplasm while the DOX 
was mainly entrapped in the nucleus. The prodrug showed higher cytotoxicity and 
achieved much lower IC50 values in comparison with the pristine DOX, especially for 
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 MCF-7 cancer cells. Longer time treatment resulted in better cytotoxicity. Further in vivo 





















 5 IN VIVO INVESTIGATION ON PHARMACOKINETICS AND 
BIODISTRIBUTION OF THE TPGS-DOX CONJUGATE 
 
5.1 Introduction 
The in vivo pharmacokinetics (PK) and biodistribution (BD) of the TPGS-DOX conjugate 
were investigated on rats in comparison with commercial DOX formulation. The 
noncompartmental PK analysis, which estimates the exposure to a drug by the 
determining the area under the curve of a concentration-time graph, was employed to test 
the in vivo therapeutic effects of the TPGS-DOX conjugate. Quite a few methods have 
been developed to determine the drug level in blood and tissues. Here HPLC detection 
method was utilized due to its easy handling with acceptable sensitivity and selectivity. 
The blood and organs collected from the rats after drug administration needed to be 
treated through liquid-liquid extraction and no internal standard was needed in assay. And 
then the samples were measured by HPLC using fluorescence detection.   
 
5.2 Materials and Methods 
5.2.1 Animal  
Male Sprague-Dawley (SD) rate, which were 150-200 g and 4-5 weeks old, were provided 
by the Laboratory Animals Centre of Singapore and maintained at the Animal Holding 
Unit (AHU) of National University of Singapore. They were kept in well-ventilated rooms 
at a temperature of 25±2 °C and a humidity of 50-60% under nature lighting conditions. 
All rats caring and handling procedures and protocols were approved by Institutional 
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 Animal Care and Use Committee (IACUC), Office of Life Science, National University of 
Singapore under the authority of Animal Welfare Act (AWA). 
 
5.2.2 In Vivo Pharmacokinetics 
5.2.2.1  Drug Administration  
The SD rats were randomly assigned to two groups with each of four rats; one group for 
i.v. administration of free DOX and the other for that of TPGS-DOX. Before drug 
administration, commercial DOX or TPGS-DOX conjugate were diluted in normal saline 
containing 1.9% w/v NaCl to obtain an estimated injection volume of 1-1.5 ml. 
Intravenous injection was given via the tail vein at a 5 mg/kg equivalent drug dosage. All 
animals were observed for mortality, general condition and potential clinical signs. 
 
5.2.2.2  Blood Collection and Sample Analysis 
The blood samples were collected by heparinized tube at 0 (pre-dose), 10, 30 min, 1, 2, 4, 
8, 12, 24, 48, 72 h post-treatment. Plasma samples were harvested by centrifugation at 
1500×g for 10 min and stored at -20 oC until analysis. Liquid-liquid extraction was 
performed prior to the HPLC analysis. Briefly, the plasma (100 µL) was mixed with 100 
µL of 10 mM phosphate-buffered saline (pH 7.8). The drug was extracted by 
dichloromethane-isopropanol (4:1, v/v) on a vortex-mixer for 90 s. Upon centrifugation at 
2000×g for 15 min, the upper aqueous layer was removed by aspiration and the organic 
layer was transferred to a glass tube and evaporated under nitrogen at room temperature 
overnight. The residue was dissolved in 100 µL of the HPLC mobile phase (1/15 M 
KH2PO4/CH3CN=75:25 v/v, pH 4.16, adjusted with H3PO4) by vortex and transferred to 
auto sampler vials containing limited-volume inserts (100 µL). The standards needed to be 
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 prepared using blank plasma with a series concentration of commercial DOX (0.05 µg/ml-
100µg/ml), followed by the same treatment as the samples done. The drug concentration 
in samples was calculated using the standard calibration curve. 
 
For the HPLC analysis, the drug concentration in plasma was determined using Agilent® 
1100 Series installed with Agilent® Eclipse XDB-C18 column with 5 µm pore size. The 
mobile phase was delivered at a rate of 1 mL/min. Twenty µL of sample were injected and 
the column effluent was detected with a fluorescence detector (Ex 470 nm, Em 585 nm) 
(Watson, Stewart et al. 1985; Park, Lee et al. 2006).  
 
5.2.2.3  Pharmacokinetic Parameters 
Non-compartmental Analysis (NCA), done by Kinetica Software (Thermo Electron 
Corporation, USA), provides an estimate of the kinetic parameters of a drug based on 
statistical moment theory. As for the specific parameters, the maximum drug 
concentration (Cmax) and the corresponding time (tmax) can be observed from the plasma 
concentration vs time curve. The elimination half-life (t1/2), an important index, can be 
calculated as㏑ 2/λn, in which λn is the elimination constant obtained via log-linear 
regression analysis of the terminal phase of the profile. The area under the curve (AUC) 
and area under the first moment (AUMC) can be figured out using log-linear trapezoid 
rule. The mean residence time (MRT) is calculated as AUMC/AUC. Apparent volume of 
distribution at steady state (Vss) and plasma clearance (CL) were obtained as Dosage × 
AUMCinf/(AUCinf)2 and Dosage/AUCinf, respectively, in which AUMCinf and AUCinf 
mean the corresponding value from 0 to infinity. 
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5.2.3 In Vivo Biodistribution 
5.2.3.1  Drug Administration  
The SD rats were randomly assigned to two groups, i.e. Group A with i.v. injection of the 
pristine DOX suspension and Group B of the TPGS-DOX conjugation at the equivalent 5 
mg/kg, respectively. Each group has 4 sets corresponding to 4 time points, and each set 
having 3 rats. Before drug administration, commercial DOX or TPGS-DOX conjugate 
were diluted in normal saline containing 1.9% w/v NaCl to obtain an estimated injection 
volume of 1-1.5 ml. Intravenous injection was given via the tail vein at a 5 mg/kg 
equivalent drug dosage. All animals were observed for mortality, general condition and 
potential clinical signs. 
 
5.2.3.2  Tissues Collection and Samples Analysis 
Animals in each set were sacrificed by cardiac stick exsanguinations at 0.5, 2, 8 and 24 h 
respectively after the injection and tissues (heart, spleen, stomach, lung, intestine, kidney 
and liver) were collected. The tissues were then washed with saline and stored at -80oC 
prior to analysis.  
 
For the analysis, the tissues were freeze-dried, homogenized. After that, 30 mg organ for 
each was mixed with 300 µL PBS, followed by extraction and HPLC analysis as the blood 
samples done. The standards of different organs needed to be prepared using the blank 
tissues collected from the rats without any drug administration. A series of commercial 
DOX was added in the different blank organs respectively and then the standards were 
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 treated in the same way as the samples done. The drug level in organs was figured out 
using the standard calibration curve. 
 
5.2.3.3 Statistics 
Statistical analysis was conducted by using the student’s t-test with p<0.05 as significant 
difference. 
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Fig 5-1 Pharmacokinetic profile of the pristine DOX and the DOX-TPGS conjugate after 




 The plasma concentration level of DOX was determined after a single intravenous 
injection of the commercial DOX or the TPGS-DOX conjugate at a dose of 5 mg/kg DOX 
equivalent in male SD rats, which is shown in Fig 5-1 in a period up to 72 h. The free 
DOX rapidly disappeared from the circulation due to its short half-life. In contrast, the 
TPGS-DOX conjugate showed a much longer circulation time. Both formulations reached 
the highest level 10 min after the injection, which is 199.5±38.0 ng/mL for the pristine 
DOX and 4,110±1,419 ng/mL (p<0.01) for the TPGS-DOX conjugate. The drug 
concentration of the TPGS-DOX conjugate achieved much higher drug concentration in 
the plasma than the pristine DOX did all the time in the experiment (p<0.05), but lower 
than the peak concentration (16.4 µM) with the MTD (maximum tolerated dose) 
administration (8mg/kg) of free DOX (Houba, Boven et al. 2001). 
 
 
Table 5-1 Pharmacokinetic parameters of the TPGS-DOX conjugate vs the pristine DOX 
i.v. injected in the SD rats at the equivalent 5 mg/kg dose 
 
Parameter DOX TPGS-DOX 
t1/2 a (h) 2.53±0.26 9.65±0.94 
teffectb (h) 9.90±0.51 62.1±2.53 
MRTc (h) 2.86±0.39 10.9±1.87 
AUC0-∞d (h·ng/mL) 288±54 6812±2149 
CLtote (L/h/kg) 17.3±3.08 0.734±0.164 
Vdssf (L/kg) 49.6±6.13 8.02±0.91 
 
a half-life time; b therapeutic effective period; c mean residence time; d area under the 
curve; e total clearance; f volume of distribution at steady state. 
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 The pharmacokinetic parameters are summarized in Table 5-1. It can be seen from the 
Table 5-1 that the half-life of the drug was 9.65±0.94 h for the TPGS-DOX conjugate and 
2.53±0.26 h for the original DOX, 3.81 times longer (p<0.01). Our measurement of the 
half-life of the doxorubicin at the 5 mg/kg dose was in good agreement with that found 
from the literature (Gao, Lee et al. 2005).  The mean residence time of the drug in the 
plasma was 10.9±1.87 h for the TPGS-DOX conjugate vs 2.86±0.39 h for the pristine 
DOX, also 3.81 times longer (p<0.05) since it has the same physical meaning as the half-
life. The therapeutic effective period was 62.1±2.53 h for the TPGS-DOX conjugation and 
9.90±0.51 h for the DOX alone, 6.27 times longer (p<0.05) (the minimum effective level 
10 nM was found from the literature (Gavenda, Ševčík et al. 2001)). This may be due to 
the enhanced permeability and retention effect (ERF) by the TPGS conjugation. As 
prolonged plasma circulation is the driving force for increased tumor targeting (Seymour, 
Miyamoto et al. 1995), the conjugate was supposed to show improved therapeutic efficacy. 
Indeed, the area-under-the-curve (AUC), which is a key therapeutic index of a drug, was 
6,810±2149 h·ng/mL for the TPGS-DOX conjugate and 288±54 h·ng/mL for the DOX 
alone, 23.6 times larger (p<0.05). The volume distribution at steady state was 8.02±0.91 
L/kg for the TPGS-DOX conjugate and 49.6±6.13 L/kg for the DOX alone, which was 
6.18 times smaller (p<0.05), and the total clearance of the drug from the plasma was 
0.763±0.164 L/h/kg for the TPGS-DOX conjugate vs 17.3±3.08 L/h/kg for the DOX alone, 
22.7 times longer (p<0.05). All these results showed the significant enhancement of the 
drug’s pharmacokinetics through TPGS conjugation. It should be emphasized that, 
although polymer-drug conjugation enhanced the pharmacokinetics of the drug in general, 
our TPGS-DOX conjugate showed the most significant effects compared with other 
polymer-DOX conjugates in the literature (Senter, Svensson et al. 1995; Veronese, 
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 Schiavon et al. 2005). Although both increased AUC and retention time were 
demonstrated but they were not as significant as the TPGS-DOX had achieved, compared 
to the pristine DOX. 
 
5.3.2 Biodistribution 
The distribution of DOX in solid tissues such as heart, lung, spleen, liver, gastric, intestine 
and kidney was investigated at four time points: 0.5, 2, 8 and 24 h. The results are shown 
in Fig 5-2 with graph (a) for pristine DOX and graph (b) for the TPGS-DOX 
administration of 5 mg/kg doxorubicin dose. It can be seen that TPGS conjugation 
significantly changed the biodistribution of the drug. The peak concentrations were 
detected at 0.5 or 2 h for DOX administration while most peak concentrations were found 
at 2 or 8 h for the TPGS-DOX conjugate. TPGS conjugation delayed the time of the peak 
concentrations and reduced their magnitude, which may imply reduced side effects and 
thus have clinical significance. Such an advantage of TPGS conjugation may be attributed 
to the slower penetration of the prodrug into the tissues. For DOX, the highest 
concentration was found in heart (50.08±5.27 µg/g at 2h) followed by stomach 
(46.97±12.61 µg/g at 2 h), lung (44.44±12.85 µg/g at 2 h), kidney (42.63±9.27 µg/g at 0.5 
h) and intestine (41.71±4.92 µg/g at 2 h). On the contrary, the peak concentration in these 
tissues for the TPGS-DOX conjugate dropped by 5.4-, 7.3-, 2.2-, 2.4- and 5.3-fold, which 
was 9.22±6.69 µg/g at 2 h, 6.44±5.93 µg/g at 0.5 h, 20.19±11.2 µg/g at 8 h, 17.66±9.56 
µg/g at 2 h and 7.83±4.66 µg/g at 2 h, respectively (p<0.05). The conjugate presented a 
little higher DOX peak levels than the free drug in spleen (22.52±8.50 vs 12.68±0.74 µg/g) 
and liver (17.57±3.24 vs 14.70±6.13 µg/g) at 2 and 8 h, respectively (p>0.05). 
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 Table 5-2 summarizes the AUC values of DOX in various tissues after intravenous 
injection of the TPGS-DOX conjugate vs the free DOX. In comparison with that of the 
DOX, the AUC of the TPGS-DOX conjugate was a bit higher in liver (262±47 vs 228± 20 
µg·h/g, p=0.31) and spleen (335±43 vs 127.0±32.6 µg·h/g, p<0.05), comparable in lung 
(313±50 vs 304±86 µg·h/g, p=0.88) and kidney (169.4±39.6 vs 166.3±21.6 µg·h/g, 
p=0.91), and lower in heart (155.2±33.1 vs 307±64 µg·h/g, p<0.05), stomach (114.3±38.6 
vs 313±14 µg·h/g, p<0.01) and intestine (86.7±20.1 vs 246±51 µg·h/g, p<0.01). The 
TPGS-DOX showed great superiority in decreasing the AUC in heart by over 5 times, 
which was indicated only 3 times decline for prodrug DOX-GA3 (Houba, Boven et al. 
2001) and other polymer-DOX conjugate (Tomlinson, Heller et al. 2003; Veronese, 

































































Fig 5-2 The DOX levels (µg/g) in heart, lung, spleen, liver, stomach, intestine and kidney 
after i.v. administration  at 5 mg/kg equivalent drug of (a) the free DOX, (b) the TPGS-




DOX is a lipophilic molecule and can rapidly penetrate into normal tissues (Houba, Boven 
et al. 2001), which may account for unfavorable side-effects. The hydrophilic TPGS 
moiety of the TPGS-DOX would prevent the rapid diffusion of the prodrug into tissue 
cells. This is consistent with the delayed time and decreased magnitude of the peak drug 
concentration in normal tissues of the TPGS-DOX conjugate. Significantly higher kidney 
level of the free drug was observed at 0.5 and 2 h due to its on-going renal elimination, 
which was also consistent with the faster clearance of the free drug. High accumulation of 
the prodrug in liver and spleen may suggest that these two organs be the major ones for 
the clearance, in which the prodrug was preferentially uptaken by the reticuloendothelial 
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 system. More importantly, in contrast with the increased level of DOX in liver and spleen 
after TPGS-DOX conjugate administration, the concentrations of the drug in heart, 
stomach and intestine for the TPGS-DOX administration were reduced much more. As the 
major side effect of DOX is considered as serious cardiac and gastrointestinal toxicity 
(Mishra and Jain 2000), the TPGS-DOX prodrug significantly impaired such limitations 
and showed great superiority over the free DOX. 
 
 
Table 5-2 AUC values (µg·h/g) of biodistribution in various organs after intravenous 
injection of the free DOX and the TPGS-DOX conjugate to rats at 5 mg/kg equivalent 
dose 
 
 heart lung spleen liver stomach intestine kidney 























5.4 Conclusions  
The in vivo pharmacokinetics investigation showed that the TPGS-DOX resulted in much 
higher AUC and much longer half-life than the original DOX, which implied enhanced 
therapeutic effects. The peak value of the drug concentration in the tissues was reduced 
and the time at which the peak concentration was delayed, which implied reduced side 
effects. The biodistribution investigation showed that the drug accumulation for the 
TPGS-DOX administration was higher in liver and spleen, and lower in heart, stomach 
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 and intestine than that for the pristine DOX administration, which indicated the reduced 























 6 CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
The main objective of this project is to develop a novel polymeric anti-cancer drug 
conjugate, TPGS-Doxorubicin, for cancer chemotherapy, which comprises prodrug 
synthesis and confirmation, in vitro characterization of release, cytotoxicity and cellular 
uptake, in vivo investigations in pharmacokinetics and biodistribution. There has been a 
lot of work on polymer-drug conjugation, specifically on PEG-DOX conjugation. To our 
knowledge, however, TPGS conjugation represents a novel idea in polymer-drug 
conjugation strategy since TPGS is a PEGylated vitamin E, which can further improve the 
cellular uptake and half-life and thus the therapeutic effects of the drug.  
 
As chapter 3 indicated, TPGS-DOX conjugate was successfully synthesized by chemical 
attachment between the carboxyl group in TPGS-SA and the primary amine group in 
DOX in the presence of the coupling agent. 1H NMR, FT-IR and GPC were employed to 
determine the chemical structure and molecular weight, which confirmed the success of 
the DOX conjugation onto TPGS. The drug loading efficiency of the conjugate was 
detected using microplate reader, implying 8%. Moreover, the stability study showed that 
only 12% drug was released after 5 months as stored at 4 oC, indicating DOX could be 
stably attached to TPGS. In chapter 4, in vitro investigation demonstrated that the prodrug 
could release DOX for more than 10 days without initial burst in a controlled way under 
different pH values. Compared to free DOX, the conjugate displayed higher cellular 
uptake and better cytotoxicity in both C6 and MCF-7 cell lines. The lower IC50 values of 
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 the TPGS-DOX showed its great superiority over the existing polymeric DOX conjugates. 
Besides, the conjugate was found to be distributed differently in cancer cells from the free 
DOX, which may imply the different mechanism of drug delivery. At last, the in vivo 
pharmacokinetics and biodistribution were further demonstrated in chapter 5. The TPGS-
DOX conjugate resulted in controlled release in blood and tissues as well as less toxicity 
in comparison with pristine DOX. On one hand, the TPGS-DOX conjugate resulted in 
much higher AUC and much longer half-life in plasma than the original DOX, which 
implied greatly enhanced therapeutic effects. On the other hand, the peak value of the drug 
concentration in normal tissues after TPGS-DOX administration was reduced and the time 
of the peak concentration was delayed, which implied reduced side effects. 
 
All in all, the work above demonstrated that TPGS could carry doxorubicin by 
conjugation and realize controlled and sustained release under mild acidic conditions that 
allowed the transport of the prodrug to tumor cells and facilitate drug release to exert its 
therapeutic function there. The higher in vitro cellular uptake efficiency, cytotoxicity and 
much lower IC50 values of the conjugate in comparison with the pristine DOX or other 
reported polymer-DOX conjugate approved the great clinical promise of TPGS for drug 
conjugation. The in vivo pharmacokinetics index further revealed that the significant 
enhancement of the drug’s pharmacokinetics by TPGS conjugation. As for the 
biodistribution, the drug accumulation for the TPGS-DOX administration was much lower 
in heart, gastric and intestine than that for the pristine DOX administration, which greatly 
impaired the limitation of commercial doxorubicin. The TPGS-DOX prodrug showed 
great potential to become a novel dosage form of doxorubicin and the methodology can 




To further improve the TPGS-drug conjugate in cancer chemotherapy, the following work 
is recommended: 
 To develop TPGS prodrug for other hydrophobic drug such as Docetaxel, hydrophilic 
drug or protein drug; 
 To transplant different tumor models in animals and evaluate the inhibition effect of 
TPGS-drug conjugate (Xenograft); 
 To apply the TPGS-drug conjugate in clinic phase I test for further investigation in 
therapeutic and side effects; 
 To conjugate targeting agent on to the prodrug for targeted delivery of the drug, for 
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